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Introduction 
 The life expectancy of HIV-infected patients has increased as a result of highly 
active antiretroviral therapy (HAART). Consequently, patients and physicians are dealing 
with neurologic complications from the HIV disease, from concurrent diseases, and from 
drugs used to treat it. Peripheral neuropathy is the most common HIV-associated 
neurologic complication. The spectrum and the frequency of this complication are 
changing due to introduction of new antiretroviral drugs, an aging HIV-infected 
population, and the emergence of other long-term complications of HIV and/or its 
treatment.Several forms of neuropathy may occur, depending on the level of 
immunosuppression and the presence of risk factors. There is a great need for an 
improved understanding of these complications and their pathogenetic mechanisms, for 
the development of effective therapies that provide adequate symptomatic relief and halt 
or reverse the damage to the nerves. This work of dissertation has been done with an aim 
of estimating the prevalence and evaluating the risk factors associated with peripheral 
neuropathy in HIV infected patients of our region.        
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Aims of the study 
 
1. To study the prevalence of peripheral neuropathy in HIV infected      
patients. 
 
2. To study the risk factors associated with the development of      
peripheral neuropathy in HIV infected patients 
 
3. To study the clinical profile and various types and patterns of 
peripheral neuropathy in HIV infected   patients. 
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Review of Literature 
 
EPIDEMIOLOGY 
Human immunodeficiency virus (HIV) is a lentivirus (a member of the retrovirus 
family) that causes acquired immunodeficiency syndrome (AIDS), a condition in human 
in which the immune system begins to fail, leading to life-threatening opportunistic 
infections. Infection with HIV occurs by the transfer of blood, semen, vaginal fluid, pre-
ejaculate, or breast milk. Within these bodily fluids, HIV is present as both free virus 
particles and virus within infected immune cells. The four major routes of transmission 
are unsafe sex, contaminated needles, breast milk, and transmission from an infected 
mother to her baby at birth (vertical transmission). 
HIV infection in humans is considered pandemic by the World Health 
Organization (WHO). From its discovery in 1981 to 2006, AIDS killed more than 25 
million people. HIV infects about 0.6% of the world's population.[3] In 2005 alone, AIDS 
claimed an estimated 2.4–3.3 million lives, of which more than 570,000 were children. 
Antiretroviral treatment reduces both the mortality and the morbidity of HIV infection.   
HIV infects primarily vital cells in the human immune system such as helper T 
cells (to be specific, CD4+ T cells), macrophages, and dendritic cells. HIV infection leads 
to low levels of CD4+ T cells through three main mechanisms: First, direct viral killing of 
infected cells; second, increased rates of apoptosis in infected cells; and third, killing of 
infected CD4+ T cells by CD8 cytotoxic lymphocytes that recognize infected cells. When 
CD4+ T cell numbers decline below a critical level, cell-mediated immunity is lost, and 
the body becomes progressively more susceptible to opportunistic infections. 
HIV-1 causes most HIV infections worldwide, but HIV-2 causes a substantial 
proportion of infections in parts of West Africa. HIV-2 appears less virulent than HIV-1.   
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Most untreated people infected with HIV-1 eventually develop AIDS. These individuals 
mostly die from opportunistic infections or malignancies associated with the progressive 
failure of the immune system.[4] HIV progresses to AIDS at a variable rate affected by 
viral, host, and environmental factors; Most will progress to AIDS within 10 years of HIV 
infection: some will have progressed much sooner, and some will take much longer. 
Treatment with anti-retrovirals increases the life expectancy of people infected with HIV. 
Even after HIV has progressed to diagnosable AIDS, the average survival time with 
antiretroviral therapy was estimated to be more than 5 years as of 2005.[5] Without 
antiretroviral therapy, someone who has AIDS typically dies within a year.[6]  
 
STAGING 
HIV disease staging and classification systems are critical tools for tracking and 
monitoring the HIV epidemic and clinical management. Two major classification systems 
currently are in use: the U.S. Centers for Disease Control and Prevention (CDC) 
classification system and the World Health Organization (WHO) Clinical Staging and 
Disease Classification System.  
The CDC disease staging system assesses the severity of HIV disease by CD4 cell 
counts and by the presence of specific HIV-related conditions. The definition of AIDS 
includes all HIV-infected individuals with CD4 counts of <200 cells/µL (or CD4 
percentage <14%) as well as those with certain HIV-related conditions and symptoms. 
The CDC system is used in clinical and epidemiologic research.  
In contrast to the CDC system, the WHO Clinical Staging and Disease 
Classification System (revised in 2005) can be used readily in resource-constrained 
settings without access to CD4 cell count measurements or other diagnostic and 
laboratory testing methods. The WHO system classifies HIV disease on the basis of 
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clinical manifestations that can be recognized and treated by clinicians in diverse settings, 
including resource-constrained settings, and by clinicians with varying levels of HIV 
expertise and training.  
CDC Classification System for HIV Infection  
The CDC categorization of HIV/AIDS is based on the lowest documented CD4 
cell count (Table 1) and on previously diagnosed HIV-related conditions (Tables 2 and 3). 
For example, if a patient had a condition that once met the criteria for Category B but 
now is asymptomatic, the patient would remain in Category B. Additionally, 
categorization is based on specific conditions, as indicated below. Patients in categories 
A3, B3, and C1-C3 are considered to have AIDS.  
Table 1. CDC Classification System for HIV-Infected Adults and Adolescents 
 Clinical Categories 
CD4 Cell 
Categories 
A  
Asymptomatic, 
Acute HIV, or 
PGL (persistant 
generalised 
lymphadenopathy) 
B  
Symptomatic 
Conditions, not A 
or C 
C  
AIDS-Indicator 
Conditions 
(1) ≥500 cells/µL A1 B1 C1 
(2) 200-499 
cells/µL 
A2 B2 C2 
(3) <200 cells/µL A3 B3 C3 
 
Table 2. CDC Classification System: Category B Symptomatic Conditions  
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Category B symptomatic conditions are defined as symptomatic conditions occurring in 
an HIV-infected adolescent or adult those meet at least 1 of the following criteria: 
a) They are attributed to HIV infection or indicate a defect in cell-mediated 
immunity.  
b) They are considered to have a clinical course or management that is complicated 
by HIV infection.  
Examples include, but are not limited to, the following: 
- Bacillary angiomatosis  
- Oropharyngeal candidiasis (thrush)  
- Vulvovaginal candidiasis, persistent or resistant  
- Pelvic inflammatory disease (PID)  
- Cervical dysplasia (moderate or severe)/cervical carcinoma in situ  
- Hairy leukoplakia, oral  
- Idiopathic thrombocytopenic purpura  
- Constitutional symptoms, such as fever (>38.5°C) or diarrhea lasting >1 month  
- Peripheral neuropathy  
- Herpes zoster (shingles), involving ≥2 episodes or ≥1 dermatome 
 
 
 
 
 
 
 
Table 3. CDC Classification System: Category C AIDS-Indicator Conditions 
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- Bacterial pneumonia, recurrent (≥2 episodes in 12 months)  
- Candidiasis of the bronchi, trachea, or lungs  
- Candidiasis, esophageal  
- Cervical carcinoma, invasive, confirmed by biopsy  
- Coccidioidomycosis, disseminated or extrapulmonary  
- Cryptococcosis, extrapulmonary  
- Cryptosporidiosis, chronic intestinal (>1-month duration)  
- Cytomegalovirus disease (other than liver, spleen, or nodes)  
- Encephalopathy, HIV-related  
- Herpes simplex: chronic ulcers (>1-month duration), or bronchitis, pneumonitis, or        
esophagitis  
- Histoplasmosis, disseminated or extrapulmonary  
- Isosporiasis, chronic intestinal (>1-month duration)  
- Kaposi sarcoma  
- Lymphoma, Burkitt, immunoblastic, or primary central nervous system  
- Mycobacterium avium complex (MAC) or M kansasii , disseminated or extrapulmonary  
- Mycobacterium tuberculosis , pulmonary or extrapulmonary  
- Mycobacterium , other species or unidentified species, disseminated or extrapulmonary  
- Pneumocystis jiroveci (formerly carinii ) pneumonia (PCP)  
- Progressive multifocal leukoencephalopathy (PML)  
- Salmonella septicemia, recurrent (nontyphoid)  
- Toxoplasmosis of brain  
- Wasting syndrome due to HIV (involuntary weight loss >10% of baseline body weight) 
associated with either chronic diarrhea (≥2 loose stools per day ≥1 month) or chronic 
weakness and documented fever ≥1 month 
 
 
WHO Clinical Staging of HIV/AIDS and Case Definition 
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• The clinical staging and case definition of HIV for resource-constrained settings 
were developed by the WHO in 1990 and revised in 2007. For the purpose of the 
WHO staging system, adolescents and adults are defined as individuals aged ≥15 
years. 
Clinical Stage I: 
• Asymptomatic 
• Persistent generalized lymphadenopathy 
Clinical Stage II: 
• Moderate unexplained* weight loss (under 10% of presumed or measured body 
weight)**  
• Recurrent respiratory tract infections (sinusitis, tonsillitis, otitis media, 
pharyngitis)  
• Herpes zoster  
• Angular chelitis  
• Recurrent oral ulceration  
• Papular pruritic eruptions  
• Seborrhoeic dermatitis  
• Fungal nail infections  
Clinical Stage III: 
• Unexplained* severe weight loss (over 10% of presumed or measured body 
weight)**  
• Unexplained* chronic diarrhoea for longer than one month  
• Unexplained* persistent fever (intermittent or constant for longer than one month)  
• Persistent oral candidiasis  
• Oral hairy leukoplakia  
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• Pulmonary tuberculosis  
• Severe bacterial infections (e.g. pneumonia, empyema, pyomyositis, bone or joint 
infection, meningitis, bacteraemia)  
• Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis  
• Unexplained* anaemia (below 8 g/dl), neutropenia (below 0.5 billion/l) and/or 
chronic thrombocytopenia (below 50 billion/l)  
Clinical Stage IV: 
• HIV wasting syndrome  
• Pneumocystis pneumonia  
• Recurrent severe bacterial pneumonia  
• Chronic herpes simplex infection (orolabial, genital or anorectal of more than one 
month’s duration or visceral at any site)  
• Oesophageal candidiasis (or candidiasis of trachea, bronchi or lungs)  
• Extrapulmonary tuberculosis  
• Kaposi sarcoma  
• Cytomegalovirus infection (retinitis or infection of other organs)  
• Central nervous system toxoplasmosis  
• HIV encephalopathy  
• Extrapulmonary cryptococcosis including meningitis  
• Disseminated non-tuberculous mycobacteria infection  
• Progressive multifocal leukoencephalopathy  
• Chronic cryptosporidiosis  
• Chronic isosporiasis  
• Disseminated mycosis (extrapulmonary histoplasmosis, coccidiomycosis)  
• Recurrent septicaemia (including non-typhoidal Salmonella)  
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• Lymphoma (cerebral or B cell non-Hodgkin)  
• Invasive cervical carcinoma  
• Atypical disseminated leishmaniasis  
• Symptomatic HIV-associated nephropathy or HIV-associated cardiomyopathy   
Footnotes: 
• * Unexplained refers to where the condition is not explained by other conditions.  
• ** Assessment of body weight among pregnant woman needs to consider the 
expected weight gain of pregnancy.  
 
NEUROLOGICAL COMPLICATIONS OF HIV 
In the early 1980s, as the systemic manifestations of the acquired 
immunodeficiency syndrome (AIDS) were first described, investigators realized that 
human immunodeficiency virus (HIV) infection could affect the nervous system at every 
level [7]. The spectrum of neurological disorders is broad and involves the central 
nervous system, or CNS (brain and spinal cord) and the peripheral nervous system, or 
PNS (nerves outside the brain and spinal cord, and related muscle). 
The causes of neurological disease are various: autoimmune reactions due to 
immune disregulation, opportunistic infections (OIs), metabolic and nutritional 
derangement due to or associated with AIDS, the direct attack on nerve tissue by HIV, 
and the toxic effects of drugs used to treat HIV and OIs.  
PERIPHERAL NEUROPATHY IN HIV INFECTION 
Although every part of the neuraxis with the exception of the neuromuscular 
junction is susceptible to HIV infection, the peripheral nervous system is one of the 
frequent targets and the most common neurologic problem. The major form of peripheral 
neuropathy in HIV disease is distal symmetric polyneuropathy (DSP) [57]. Several other 
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peripheral neuropathy types [59] are associated with HIV disease, mainly acute and 
chronic inflammatory demyelinating polyradiculoneuropathies (Guillain-Barre-like 
diseases), mononeuropathy multiplex (MM), progressive polyradiculopathy (PP), and 
autonomic neuropathy (AN). 
Distal Symmetric Polyneuropathy 
Distal symmetric polyneuropathy affects over one third of patients with AIDS [8]. 
It is rarely seen in children and is most common in the late stages of HIV disease. 
HAART (Highly Active Anti Retroviral Therapy) lessens disease progression, improves 
immunity, and significantly lowers risk of developing distal symmetric polyneuropathy.  
The clinical symptoms of distal symmetric  polyneuropathy are numbness, 
burning, and tingling sensations in the feet, usually in a symmetric pattern; paresthesias or 
aching distally in the lower extremities; and hyperesthesia (e.g., contact sensitivity, such 
as with bed sheets or socks). In late stages of distal symmetric polyneuropathy, the upper 
extremities may also be affected, although to a milder degree. 
The exam consists first of "subjective" sensory testing, where the examiner uses, 
128 Hz tuning fork, a safety pin and cotton swabs to assess vibration, thermal, pain and 
light touch sensation. It is important to check all four modalities. Next, the "objective" 
portion of the exam consists of checking the reflex pattern and muscle bulk and strength. 
In distal symmetric polyneuropathy, one would expect a diminution or loss of the ankle 
jerk reflexes. 
While depressed or absent ankle reflexes relative to the knees, is a hallmark of 
distal symmetric polyneuropathy, it is important to note that as HIV disease progresses, 
distal symmetric polyneuropathy is often combined with central nervous system disease, 
such as dementia or myelopathy. In this case, reflex testing may reveal hyperactive or 
brisk knee reflexes with normal ankle reflexes. Other clinical features of distal symmetric 
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polyneuropathy include increased vibratory thresholds and reduced pinprick and 
temperature sensation in a stocking and glove distribution. Muscle strength and joint 
position sensation are relatively normal. Symptomatic weakness appears late in the 
disease and is generally restricted to the distal intrinsic foot muscles. Another objective 
sign of distal symmetric polyneuropathy is atrophic skin change, particularly a significant 
loss of hair from the distal extremities. Nerve conduction studies can be useful to confirm 
the diagnosis of distal symmetric polyneuropathy by revealing abnormal sensory nerve 
potential amplitudes and conduction velocity, especially of the sural nerve. 
Other Causes of distal symmetric polyneuropathy: It is critical to differentiate 
HIV-related distal symmetric polyneuropathy from distal symmetric polyneuropathy 
resulting from other causes, such as diabetes mellitus, vitamin B12 deficiency, alcohol 
abuse, or drug toxicities (e.g., vincristine, used to treat Kaposi's sarcoma and lymphoma; 
isoniazid and thalidomide, used to treat aphthous ulcers). 
 
Differentiating HIV-Related Distal Symmetric Polyneuropathy from Neurotoxic 
Neuropathy 
The major antiretroviral neurotoxins [11] are the dideoxynucleoside analogues 
didanosine (ddI), zalcitabine (ddC), and stavudine (d4T). Other forms of NRTIs (3TC 
[Epivir], AZT [Retrovir], and abacavir [Ziagen], along with non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) and protease inhibitors, are not generally associated 
with peripheral neuropathy. 
Hydroxyurea, a drug used to treat cancer that may also help certain anti-HIV drugs 
work better, appears to increase the risk of peripheral neuropathy. Other drugs used in the 
treatment of HIV-related disorders that can increase the chance of developing peripheral 
neuropathy include:  
13 
 
• Isoniazid, (INH), used to treat tuberculosis  
• Metronidazole, used to treat amoebic dysentery   
• Vincristine, used for Kaposi's sarcoma and non-Hodgkin's lymphoma  
• Thalidomide, used to treat cancers and severe mouth ulcers  
• Ethambutol, used to treat Mycobacterium avium complex (MAC)   
The clinical features of nucleoside-related distal symmetric polyneuropathy and 
distal symmetric polyneuropathy resulting from primary HIV infection are so similar as to 
be virtually indistinguishable on bedside examination. Simpson et al. reported that the 
prevalence of HIV-associated neuropathy increases as immune function deteriorates. [9] 
This relationship suggests that a patient presenting with high CD4 counts may not be 
suffering from HIV-associated distal symmetric polyneuropathy alone, but also from 
neurotoxicity or other underlying conditions. 
In neurotoxic distal symmetric polyneuropathy, the standard time to resolution of 
neuropathy after discontinuation of the neurotoxin is at least eight weeks. Many patients 
improve within one to three weeks following discontinuation of zalcitabine but resolution 
of distal symmetric polyneuropathy may also take considerably longer. Patients taking 
higher doses of zalcitabine (e.g., 0.06 mg/kg/ day) experience a "coasting period" of three 
to six months following withdrawal of the drug, during which time the symptoms of 
neuropathy may intensify before improving. [10] A maximum didanosine dosage of 12.5 
mg/ kg/day has been suggested to avoid the development of distal symmetric 
polyneuropathy. Immunosuppressed patients with low CD4 cell counts may develop 
didanosine- associated neuropathy at lower doses. [9]   
 
Pathology and pathophysiology of Distal Symmetric Polyneuropathy  
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Length-dependent axonal degeneration of sensory fibers, with little evidence of 
nerve-fiber regeneration, characterizes distal-sensory polyneuropathy. Both large 
myelinated and unmyelinated nerve fibers are lost. The overt neuropathological changes 
include inflammatory infiltrates of lymphocytes and activated macrophages, low numbers 
of dorsal-root ganglion neurons, and high numbers of nodules of Nageotte. [12]. The 
envelope glycoprotein, gp120, may produce neurotoxicity within the dorsal root ganglion.  
The prominent presence of proinflammatory cytokines, including tumor necrosis factor, 
interferon, interleukin 6, and other inflammatory mediators including nitric oxide, has 
been shown in dorsal root ganglia.  
Little is known about the specific pathological changes of antiretroviral-toxic 
neuropathy, although sural-nerve biopsies have shown severe axonal destruction, 
prominent in unmyelinated fibers. Prominent mitochondrial abnormalities have also been 
shown, and are thought to underlie the pathogenesis of antiretroviral-toxic neuropathy. 
This is further supported by evidence of increased serum lactate concentrations and 
reduced serum concentrations of acetylcarnitine in patients with antiretroviral-toxic 
neuropathy. Dideoxynucleoside inhibition of neurite outgrowth is dose-dependent. The 
mechanism of neuronal injury from zalcitabine and other neurotoxic drugs seems to be 
distinct from the neurotoxicity of the envelope glycoprotein, gp120. Thus, zalcitabine 
mediates injury through neuronal necrosis, whereas gp120 is predominantly apoptotic and 
mediated through Schwann cells.  
Treatment of Distal Symmetric Polyneuropathy 
The treatment of HIV-associated distal symmetric polyneuropathy is primarily 
symptomatic. Correction of metabolic and nutritional abnormalities. Pain management 
begins with nonopioid analgesics, such as acetaminophen and nonsteroidal anti-
inflammatory agents. With persistent and more disabling pain, adjuvant agents such as 
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tricyclic antidepressants may be added. Amitriptyline to be started at 10 to 25 mg at 
bedtime and increased by 25 mg increments on a weekly basis to a maximum of 100 to 
150 mg. Side effects include anticholinergic toxicity and if these side effects persist and 
limit dose escalation, a tricyclic antidepressant with a lower anticholinergic profile may 
be used (e.g., nortriptyline or desipramine). Anticonvulsants such as phenytoin, 
carbamazepine, gabapentin and lamotrigine may also provide relief from pain.  
Plasmapheresis has been ineffective in reducing symptoms of Distal Symmetric 
Polyneuropathy. Topical capsaicin may reduce the pain of Distal Symmetric 
Polyneuropathy. When increasing levels of disabling pain are refractory to the above-
mentioned agents, a strong opioid or long-lasting opioid agonist (e.g., methadone or long-
acting morphine or fentanyl) may be considered. 
Inflammatory Demyelinating Polyneuropathy   
Inflammatory demyelinating polyneuropathy is a relatively infrequent neuropathic 
complication of HIV infection seen most often in patients who are HIV seropositive but 
otherwise asymptomatic. The acute form (AIDP) may occur at the time of primary HIV 
infection. AIDP is clinically characterized by rapidly progressive muscle weakness 
involving two or more extremities, accompanied by generalized areflexia. Bilateral 
peripheral facial nerve weakness may be present. The chronic form (CIDP) is clinically 
distinguished by its slower progression; its clinical course may be monophasic or 
relapsing. Cerebrospinal fluid analysis is important in the diagnosis of HIV-associated 
inflammatory demyelinating polyneuropathy. The majority of HIV-infected patients have 
a CSF lymphocytic pleocytosis (10 to 50 cells/mm3), with mild elevation of protein. This 
finding serves to distinguish them from HIV-negative inflammatory demyelinating 
polyneuropathy patients, whose CSF is typically acellular. [13] Electrophysiologic studies 
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reveal evidence of demyelination in patients with inflammatory demyelinating 
polyneuropathy.  
Inflammatory demyelinating polyneuropathy is primarily treated by 
immunomodulation (corticosteroids, plasmapheresis, and high-dose intravenous 
immunoglobulin). In severely compromised patients (CD4 count less than 50 cells/mm3), 
anti-cytomegalovirus (CMV) therapy with ganciclovir, foscarnet, or cidofovir, singly or 
in combination, is warranted.   
Mononeuritis Multiplex 
Mononeuritis multiplex is a rare complication that occurs in either early or late 
stages. [14] When mononeuritis multiplex occurs early, it is often the result of a self-
limited dysimmune neuropathy or vasculitis. In patients with long-standing HIV-1 
infection and CD4 cell counts less than 50/μL, an association with cytomegalovirus 
(CMV) infection has frequently been noted. Mononeuritis multiplex has also been 
associated with varicella zoster [15] and hepatitis C infections [54].  Multifocal sensory 
and motor abnormalities in the distribution of cutaneous nerves, mixed nerves, and nerve 
roots, including cranial neuropathies, constitute the typical neurologic presentation of 
MM. MM associated with CD4 counts greater than 200 cells/mm3 generally has a limited 
distribution and is characterized by the acute onset of sensory or motor deficits limited to 
one or a few peripheral or cranial nerves [16]. These deficits usually resolve 
spontaneously or within several months of receiving immunomodulating therapy.  
Patients with advanced immunodepression develop an extensive and more rapidly 
progressive form of MM, which may simulate other peripheral neuropathies, such as 
inflammatory demyelinating polyneuropathy or progressive polyradiculopathy. The 
diagnosis of mononeuritis multiplex is supported by electrophysiologic examination that 
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reveals a multifocal pattern of reduction in evoked sensory and motor compound muscle 
action potential amplitudes.  
Progressive Polyradiculopathy 
Progressive polyradiculopathy is an uncommon but well-described complication 
of HIV infection. The incidence is thought to have declined in the era of HAART. It is 
usually attributed to CMV infection [17]. However, it can be caused by other conditions, 
including lymphoma, [18] syphilis, [19] mycobacterial infections, [20] herpes simplex 
virus,[21]and cryptococcus [22]  
Progressive polyradiculopathy usually occurs in patients with advanced HIV 
disease and in patients with low CD4 cell counts. The onset is subacute, and the course 
extends for days to weeks. The earliest symptoms are low back pain with radiation into 
one leg followed by progressive leg weakness. If not promptly identified and treated, the 
symptoms rapidly progress to a flaccid paraplegia with bowel and bladder incontinence. 
Upper extremities may be involved late in the course [17].  Polymerase chain reaction 
amplification of CMV DNA in CSF is sensitive tool   
The major electrophysiologic abnormalities seen are widespread denervation in 
paraspinal muscles, reflecting axonal loss in lumbosacral roots with later denervation 
potentials in the leg muscles. Nerve conduction study results are usually normal. 
Although it may show enhancement of lumbosacral meninges and nerve roots, the main 
utility of magnetic resonance imaging is to exclude focal mass lesions that may be 
compressing the cauda equina. Pathologic features include marked inflammation and 
necrosis of the dorsal and ventral nerve roots with cytomegalic inclusions detectable in 
endothelial cells and nerve parenchyma.  
Current choices for the treatment of CMV disease are ganciclovir, foscarnet, and 
cidofovir. Treatment of HIV-associated progressive polyradiculopathy attributable to 
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other causes is directed at the specific cause (eg, anti-mycobacterials for tuberculosis, 
intravenous penicillin for syphilis, and chemotherapy for lymphoma-related disease).  
Autonomic Neuropathy 
Failure of the sympathetic autonomic nervous system is manifested by orthostatic 
hypotension, syncope, diarrhea, and anhidrosis. Parasympathetic abnormalities include 
resting tachycardia, impotence, and urinary dysfunction [23]. A variety of factors may 
contribute to the clinical manifestations of autonomic dysfunction, including malnutrition, 
dehydration, central and peripheral nervous system abnormalities, and drugs used to treat 
HIV-associated complications, such as tricyclic antidepressants, vincristine, and 
pentamidine. 
Diffuse infiltrative Lymphocytosis Syndrome (DILS) [58] 
Persistent CD8 lymphocytosis, named diffuse infiltrative lymphocytosis syndrome 
is characterized by a persistent peripheral blood polyclonal CD8 lymphocytosis and by 
visceral CD8 T-cell infiltration, including salivary glands, lungs, kidneys, gastrointestinal 
tract, and peripheral nerves[24]. Clinically, diffuse infiltrative lymphocytosis syndrome 
presents as acute or subacute painful multifocal, most often symmetrical, neuropathy. 
Electrophysiologic studies show axonal neuropathy. Nerve biopsy specimens are 
characterized by marked angiocentric CD8 infiltrates and abundant expression of HIV 
p24 protein without vessel wall necrosis. The treatment of diffuse infiltrative 
lymphocytosis syndrome consists primarily of standard antiretroviral therapy and/or 
corticosteroids.  
Vasculitis 
Virtually every pattern of vasculitis of small, medium, and large vessels has been 
encountered in HIV-1 infection [25] but it is a rare event, occurring in 0.3% to 1.0% of 
patients with AIDS. Vasculitis of the peripheral nerve can occur either as an isolated 
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process or, more commonly, as a manifestation of a systemic disease [26]. Vasculitic 
damage in the peripheral nervous system may present with clinical features of Distal 
Symmetric Polyneuropathy.  Peripheral nerve examination shows variable loss of 
myelinated axons and ongoing axonal degeneration with focal distribution in different 
fascicles. Perivascular inflammatory cell infiltration and fibrinoid necrosis of small 
epineural blood vessels are observed. Vasculitis is treated with corticosteroids or 
intravenous immunoglobulin. 
 
EVALUATION OF PERIPHERAL NERVE DISEASES 
VARIOUS PATTERNS OF PERIPHERAL NEUROPATHY  
Several patterns of peripheral nerve involvement are recognized. The prototypic 
and most common pattern is length-dependent, with sensory loss and pain preceding 
distal weakness. As progressively shorter nerves are affected, symptoms and signs unroll 
as a stocking up the leg. The nerve length at the knee level approximately equals the 
length innervating the hand, and with further progression, symptoms and signs unroll as a 
long glove up the arm. The distribution is usually symmetric. In. the extreme, a shield 
loss over the chest and abdomen can be observed when nerve length involvement reaches 
the circumference of the thorax. As a corollary, it is rare in polyneuropathy for there to be 
sensory involvement to the waist level, especially without marked sensory loss also to the 
elbows. Accordingly, isolated sensory loss to the upper thigh and waist levels suggests 
central nervous system localization (myelopathy). When the pattern of symptoms and 
signs includes both proximal and distal limb involvement, the pathologic process is 
usually demyelination at multifocal sites along roots and nerves (inflammatory 
polyradiculoneuropathy). Acute and chronic forms occur (AIDP and CIDP). 
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Table: Patterns of Peripheral Neuropathy and Examples of Disorders and Causes 
1. Sensory-motor symmetric(length 
dependent pattern) 
 
Diabetes, medications, toxins, metabolic 
disorders, hereditary 
 
2. Sensory-motor symmetric 
(proximal and distal pattern) 
   
Acute inflammatory demyelinating 
polyradiculopathy, chronic inflammatory  
demyelinating polyradiculopathy 
 
3. Sensory-motor asymmetric(nerve 
or plexus pattern)   
Diabetic amyotrophy, idiopathic plexopathy, 
vasculitic mononeuritis multiplex 
4. Sensory-motor asymmetric Porphyria, leprosy 
5. Sensory symmetric or asymmetric 
  
Paraneoplastic neuronopathy, Sjogren 
syndrome, idiopathic ganglionitis, vitamin B6 
toxicity, leprosy 
 
6. Motor symmetric or asymmetric 
  
Amyotrophic lateral sclerosis, multifocal motor 
conduction block neuropathy, lower motor 
neuron syndrome, Poliomyelitis  
 
7. Autonomic symmetric or 
asymmetric 
With other neuropathies (diabetes, acute 
inflammatory demyelinating 
polyradiculopathy), isolated involvement 
(amyloidosis) 
 
 
 
TIME COURSE 
An acute onset is defined as days to several weeks. Most chronic neuropathies are 
steadily progressive. A history of clear remissions and exacerbations suggests CIDP or 
other form of immune-mediated neuropathy. When the time course clearly starts in adult 
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life, an acquired neuropathy is more likely than a hereditary disorder. When the time 
course cannot be dated, a hereditary neuropathy should be considered. 
1. Acute  
 
Apoplectic 
  
Vasculitic mononeuritis multiplex, idiopathic 
plexopathy 
  Days to 
weeks 
Acute inflammatory demyelinating Polyradiculopathy, 
porphyria, acute toxic exposure, proximal diabetic 
neuropathy, paraneoplastic sensory neuropathy 
2. Chronic Years   Diabetic Polyneuropathy Chronic inflammatory 
demyelinating polyradiculopathy,idiopathic 
  Insidious Hereditary 
 
TYPES OF NERVE FIBER INVOLVEMENT 
The peripheral nervous system can be divided into somatic and autonomic 
components, and somatic peripheral nerves can be further divided into sensory and motor 
functions. Within the somatic nervous system, sensory and motor fiber involvement can 
be accurately assessed and there are neuropathies affecting sensory, motor, or both types 
of fibers. In the autonomic nervous system, separating sensory (afferent) from motor 
(efferent) involvement is difficult and both are commonly affected. Neuropathies with 
isolated autonomic nervous system involvement are rare.  
SYMPTOMS 
From the chief complaint it may not be apparent which types of nerves are 
involved.  Nerve dysfunction can be expressed as negative and positive Symptoms. 
Positive symptoms are felt to reflect inappropriate spontaneous nerve activity detected by 
the patient as uncomfortable and painful sensations, or other spontaneous phenomena. 
Negative symptoms reflect loss of nerve signaling. An important clinical difference 
between sensory and motor somatic nerves involves compensatory mechanisms. 
Following motor nerve loss, surviving motor nerves undergo collateral reinnervation to 
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reinnervate orphaned muscle fibers. This compensatory process has the effect of blunting 
weakness due to mild motor nerve loss, and clinical weakness may not be apparent to the 
patient or on physical examination until 50% of motor nerve fibers are lost (80% in 
slowly progressive denervating disorders) [27]. However, positive symptoms of cramps 
and fasciculations may be present early on as the only clinical indication of motor nerve 
involvement. The needle EMG is sensitive in detecting early motor fiber loss and will 
confirm motor nerve involvement. 
Other Important Histories in Peripheral Neuropathies 
Medical History 
Past and current medical histories like diabetes mellitus, certain collagen vascular 
disorders, chronic renal failure, and HIV infection. Inquiring about medication use is 
important, and should include vitamins and other over the counter compounds. Although 
the list of drugs, compounds, and vitamins associated with peripheral neuropathies is 
limited, drug-induced neuropathies represent readily treatable causes.  
Family History 
An important line of inquiry is the family history, seeking evidence to support a 
hereditary neuropathy. Although it may seem that a hereditary condition should be known 
within a family, the slow progression and variable expression masks detection. 
Interestingly, in large families with known Charcot-Marie-Tooth neuropathy, <30% of 
affected individuals seek medical attention for their symptoms [30]. Therefore, a careful 
line of questions can be very informative when there are clinical features suggesting a 
very long-standing condition, such as insidious onset, high arches, and hammertoes.  
SIGNS 
The clinical neurologic examination is sensitive for peripheral nerve loss and 
dysfunction, and informative for localization. It is important to emphasize that the sensory 
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examination can be challenging and confusing because responses are indirect and 
represent a patient’s interpretation of the testing questions. For example, does the sensory 
loss follow a stocking-glove (distal predominate), dermatomal, or radicular pattern?  The 
sensory examination frequently focuses on determining whether there is “large fiber” or 
“small fiber” involvement, based on a battery of simple clinical tests. However, 
psychophysical sensory perception testing suggests these distinctions are more apparent 
than real because of overlap between nociception, touch, and_pressure stimulus 
properties. Although nociceptive information is conveyed by small diameter nerve fibers, 
some nociceptive receptors are innervated by myelinated fibers, and subjects can 
distinguish sharp from dull stimuli without feeling pain. Formal psychophysical testing of 
nociception is performed using hot stimuli, cold stimuli, and special equipment, which 
contrasts to clinical sensory testing performed using cool instruments (tuning fork and 
reflex hammer) and sharp objects of varying shape (safety pin, broken wooden stick. and 
commercial pin probe). Cutaneous mechanoreceptors are mainly innervated by large 
diameter nerve fibres and are activated by a variety of moving stimuli. Vibratory 
thresholds are suitable indicators of large diameter sensory nerve dysfunction.  
Table: Positive and Negative Symptoms Associated With Nerve Damage 
   Positive symptoms  Negative symptoms 
1 Somatic 
nerves 
Sensory Pain, tingling   Numbness, lack of feeling 
 
  Motor Cramps, fasciculations Weakness, atrophy 
2 Autonomic 
nerves 
 Hyperhydrosis, 
diarrhea 
Orthostatichypotension,impotence 
anhydrosis,constipation 
Touch Stimuli 
Application of the lightest touch to the dorsum of the hand and foot represents a 
measure of low threshold mechanoreception. A series of monofilaments can be applied to 
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grade the severity of touch loss. Ten-gram filaments are useful because lack of touch 
perception at this level of pressure is associated with risk for unappreciated trauma. 
Vibration Stimuli 
Tuning forks of 128 Hz assess larger diameter nerve fiber function. Various 
comparisons can be made, and it is very important that patients are fully attentive and 
understand the need to indicate complete disappearance of the vibration. Comparisons 
between patient and examiner for the disappearance of the vibration can be measured in 
seconds. Alternatively, the time for the vibration to disappear for the patient after the 
tuning is forcefully struck can be measured in seconds. Empiric data from the great toe 
indicate that young adults lose vibration perception after 15 s, with a loss of 1 s per 
decade of age, and a loss of vibratory perception in < 10 s is abnormal at any age. 
Sharp Stimuli 
The goal is to apply a sharp stimulus without also applying undo pressure on the 
skin. A distinction between noxious and light pressure stimuli can be made by gently 
applying the two ends of a safety pin in association with a three-part question: “which is 
sharper, the first application, the second application, or are both the same?”. Inability to 
distinguish between sharp and dull supports loss of nociceptive fibers relative to low-
threshold mechanoreceptor fibers. 
Position Sense 
The ability to detect changes in digital joint position is normally exquisite (two 
degrees). It is important that patients understand the degree of sensitivity requested, and 
that they are blinded to the testing. Accordingly, misperception of joint movements 
(including falsely perceived position changes), and insensitivity to movements are 
significant for loss of large-diameter fibers. Profound joint position loss is unusual in 
peripheral nerve disorders, and often reflects central nervous system involvement. 
25 
 
Deep Tendon Reflexes 
Tendon reflexes represent an objective measure sensory nerve function. The 
myotatic reflex consists of a monosynaptic arc with large-diameter afferent (sensory) 
nerve fiber input from muscle spindle fibers and large-diameter efferent (motor) nerve 
fiber output from alpha motor neuron fibers. The reflex is much more vulnerable to 
sensory nerve fiber than to motor nerve fiber damage. Accordingly, an absent reflex is an 
objective indication of significant dysfunction of large-diameter sensory fibers. However, 
assurance that the reflex is truly absent is essential, and reinforcing maneuvers, such as 
clinching the jaw or fists and the Jendrassic maneuver, should be used before the reflex is 
considered absent.  Tendon reflexes diminish with age, and although precise data are not 
available, an absent Achilles reflex after the age of 80 years may be normal. 
Table: NINDS Scale for Deep tendon Reflexes [28] 
Grade Reflex response 
0 Reflex absent 
1 Reflex small, less than normal: includes trace response, or response 
brought out only with reinforcement 
2 Reflex in lower half of normal range 
3 Reflex in upper half of normal range 
4 Reflex enhanced, more than normal: includes clonus 
 
Motor Signs 
Detecting motor nerve involvement can be challenging due to the compensatory 
process of collateral innervation that obscures early effects of denervation. Muscle 
inspection for atrophy is useful, and the extensor digitorum brevis muscle will show the 
early change in the feet and first dorsal interosseous muscles early changes in the hands. 
A certain degree of age-related motor fiber loss occurs above 65 years and must be taken 
into consideration. Inspection for contraction fasciculations is useful to detect motor fiber 
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loss. Contraction fasciculations are visible twitches of a muscle during early activation, 
and represent the discharge of individual motor units. Such twitches are not visible in 
muscles with normal numbers of motor units, but enlarged motor units from denervation 
and collateral reinnervation are readily observed. 
Strength testing can be optimized to detect mild degrees of weakness by assessing 
muscles that can be just overcome on manual muscle testing in normal individuals. 
Informative muscles in the legs include flexors and extensors of the lesser toes and the 
extensor of the great toe, and in the arms include abductors of the second and the fifth 
digits and extensors of the fingers. Ankle dorsiflexion weakness occurs in more severe 
neuropathies, but ankle plantar flexion weakness is evident only in the most severe 
neuropathies [29]. Subtle weakness of ankle dorsiflexion and plantar flexion can be tested 
best during gait assessment by having patients walk on their heels and toes or hop on one 
leg at a time. 
Autonomic System Signs 
The autonomic nervous system is involved in many peripheral neuropathies, but 
symptoms and signs of dysautonomia are uncommonly voiced by the patient and must 
queried. Orthostatic dizziness and changes in blood pressure (a drop of >30 mmHg 
systolic pressure and >15 mmHg diastolic pressure recorded 60—90 s after standing 
support autonomic involvement. Impotence has many causes, but is frequently associated 
with autonomic neuropathy. The sicca symptoms (dry eyes and mouth) are associated 
with the Sjogren syndrome and represent end organ failure of salivary and tear glands. 
Sjogren syndrome is associated with sensory neuropathies. 
Bony Changes 
Limb inspection should include structural changes in the lower legs, feet and 
hands. The following changes may be encountered in normal individuals, but in the 
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setting of a peripheral neuropathy evaluation, suggest a long-standing condition. The 
angle between the shin and the unsupported foot is normally about 130°, and a larger 
angle suggests weakness of ankle dorsiflexor muscles, High arches and hammertoe 
deformities suggest long standing differences in the muscular forces exerted on the bones 
of the foot leading to foreshorten feet. Fallen arches can also be observed in severe 
neuropathies. Toe and foot injuries unnoticed by the patient suggest a marked degree of 
sensory loss. In the hands, flexion contractions of the fingers suggest weakness of finger 
extensor muscles. Inability to adduct the fifth digits suggests weakness of lumbrical 
muscles. 
Other Signs 
Mild dependent pedal edema, rubor, coolness and shininess of the lower leg and foot 
despite good distal arterial pulses, suggests decreased movements of distal leg muscles 
caused by mild muscle weakness, reducing the vascular return of blood and lymph. 
PATHOLOGICAL CHANGES 
Determining the primary pathologic process is important for diagnosis, treatment, 
and prognosis. The two basic pathologic processes are demyelination and axonal loss. 
They may occur together, especially when the primary process is demyelination because 
demyelination frequently involves immune attack and axons can be damaged as innocent 
bystanders. 
Electrodiagnostic testing is most able to distinguish axonal from demyelinating 
primary pathology. Nerve biopsy is less practical and informative in this regard for 
several reasons. Biopsies evaluate only a small segment of sensory nerves, and the 
relevant pathologic process may be missed. Biopsies are rarely repeated, and the time 
course of changes cannot be followed. A nerve biopsy leaves permanent dysfunction, and 
most biopsies are of sensory nerves because a localized area of numbness is tolerable 
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whereas permanent weakness is not. Nerve biopsy is important when vasculitis is a 
consideration and a biopsy can detect rare causes of neuropathy due to deposition of 
protein or other substance, such as amyloid, and abnormal cells such as sarcoid 
(granulomas) and malignant cells.  
ELECTRODIAGNOSTIC EVALUATION OF PERIPHERAL NEUROPATHY 
Questions that can be answered with electrodiagnostic testing include the following: 
(i) Which elements are involved (sensory nerves, motor nerves, or both)? 
(ii) What is the underlying pathology (primary demyelination, primary axonal, or 
mixture)?  
(iii) What is the distribution of nerve damage (single nerve, multiple nerves, length-
dependent pattern, plexus, roots, symmetric, or asymmetric)? And (iv) What is the 
time course (ongoing or chronic)? 
TECHNICAL ISSUES 
Temperature is the most important controlled variable. Limbs should be warm, 
with temperatures above 31°C. If cool, limbs should be thoroughly warmed with an 
external heat source. Supramaximal nerve stimulation must be obtained (defined as 120% 
of the current required to achieve a maximal response) to ensure a maximal nerve 
response, but over- stimulation should be avoided because it may lead to activation of 
adjacent nerves. Attention to placement of stimulation electrodes over the appropriate 
nerve results in lower currents to achieve maximal responses. Identification of anomalous 
innervation in the forearm (Martin—Gruber) is essential because it can mimic ulnar nerve 
conduction block in the forearm. 
Determination of the motor point cannot be made from anatomical landmarks and 
requires trial and error placements to determine which site yields the largest CMAP 
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amplitude [31]. Similar concerns apply to placement of recording electrodes for sensory 
nerve action potentials (SNAP) [32]. 
STATISTICAL ISSUES:    
Nerve Conduction - Limits of Normal 
Nerve conduction values are delimited by statistically derived limits of normal, 
determined from data obtained from “normal” subjects. Common limits used in nerve 
conduction studies are; (i) lower limits of normal for sensory and motor response 
amplitudes and Conduction velocities and (ii) upper limits of normal  for distal latencies 
and F- and H-wave latencies. These limits vary somewhat between laboratories, and 
commonly represent 2—3 standard deviations from normally distributed data or 95% 
confidence limits from asymmetrical data. Erroneous classifications can easily occur. For 
example, patient height (limb length) is an important variable that influences distal 
latency, F-wave latency, and conduction velocity values, and should be incorporated in 
limits of normal for these values [33].  
Conduction velocity values vary 3—5 m/s and F-wave latencies vary 6—8 ms 
over the common height range of 60 in. to 72 in. [33]. Reporting values as “normal’ or 
“abnormal” may he misleading, and the degree of the abnormality should he considered. 
A related issue is values just above or below the normal limits may not be the expected 
value for that individual. Thus, in a patient with normal extensor digitorum muscle bulk 
and strength, a CMAP value just at the lower limits of normal more likely represents 
suboptimal placement of the recording electrode than pathology because the expected 
value for a normal subject should be close to the mean value in the distribution. Similarly, 
in a young diabetic patient, a peroneal motor conduction velocity just above the lower 
limits of normal more likely reflects pathologically slowed conduction rather than normal 
conduction because the expected velocity should be close to the mean value 
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Collateral Reinnervation 
Collateral reinnervation is a compensatory process whereby surviving motor nerve 
terminals reinnervate denervated muscle fibers. The effect is to preserve both muscle 
strength and CMAP amplitude until further loss of motor nerve fibers exceeds the 
capacity of reinnervation to keep up, leading to fall of strength and CMAP amplitude. As 
a consequence of collateral reinnervation, CMAP amplitude values may remain above the 
lower limit of normal until 50—80% or more of axons have degenerated, depending on 
the rate of denervation. Mild degrees of axonal loss occur with normal aging >65 years, 
affecting the lowere limit of normal among the very elderly. Needle EMG is the most 
sensitive indicator of previous and active axonal loss. 
Symmetry of Nerve Conduction Values 
The peripheral nervous system can reasonably be considered symmetric, with the 
expectation that corresponding nerve conduction results from the right and left sides will 
be of similar value. Practical aspects of nerve conduction studies can lead to some degree 
of asymmetry of values. Asymmetric limb temperatures can affect side-to-side measures 
of amplitude distal latency and conduction velocity. Suboptimal placement of recording 
electrodes can give false asymmetric CMAP amplitude values [34].  
Table: Limits of Asymmetry in Normal Nerve Conduction Studies  
 Motor nerves Sensory nerves 
 Median Ulnar   Peroneal Tibial Median Ulnar Sural 
Amplitude 0.5 0.7 0.2 0.4 0.6 0.5 0.4 
Distal 
latency 
1.3 1.3 1.4 1.4 1.2 1.2 1.2 
Conduction 
velocity 
0.8 0.9 0.8 0.8 0.8 0.8 0.8 
F-wave 
latency 
1.1 1.1 1.1 1.1    
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Needle EMG Sampling 
Needle EMG can answer two basic questions: (i) Is there evidence for 
denervation? (ii) What is the nature of the denervation? Evidence for denervation is the 
presence of abnormal spontaneous activity in the form of positive sharp waves and 
fibrillation potentials. These potentials are very sensitive for motor nerve damage, but 
cannot distinguish between pathologic causes (neuropathic vs. myopathic). Distinguishing 
among pathologic causes can be determined by assessment of motor unit action potentials 
(MUAPs) recorded at low levels of voluntary muscle activation. Despite these 
restrictions, it is possible to distinguish neuropathic MUAPs from myopathic MUAPs by 
their recruitment pattern and by assessment of their waveforms. 
NERVE CONDUCTION STUDIES 
Normal Nerve Conduction 
A whole nerve consists of hundreds of myelinated axons whose diameters range 
from 7 to 12 m. Nerve conduction studies are typically preformed by percutaneous 
electrical stimulation of all axons in a nerve and recording the resultant evoked response. 
Sensory and motor nerves can be studied separately by varying the placement of the 
recording electrodes. The conduction velocity of a nerve fiber is proportional to its axon 
diameter, leading to a range of nerve fiber conduction velocities. Within a nerve, 35-70 
m/s for sensory nerves and 35-55 m/s for motor nerves [35]. For sensory nerves, 
recording electrodes are placed over the nerve, and the evoked response (SNAP) 
represents the summed activity of all sensory nerve fiber action potentials. For motor 
nerves, recording electrodes are placed over the muscle and the evoked response (CMAP) 
represents the summed activity of all muscle fiber action potentials. Accordingly, the 
CMAP includes synaptic delays across neuromuscular junctions. Following nerve 
stimulation, the volley of action potentials propagating down the nerve is led by the 
fastest conducting fibers. Although the rest of the volley contributes to SNAP or CMAP 
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waveforms, measures of nerve conduction timing (distal latency, conduction velocity, and 
F- and H-wave latency) focus only on the fastest conducting fibers. . The following is the 
reference values for normal motor and sensory nerve conduction studies:  
           
No. Nerve MNC/ 
SNC 
Factors Kimura 
[64] 
Misra & 
Kalita[63] 
Adams(±2 
SD) [60] 
1 Median N. MNC Latency(ms) 3.49±0.34 3.77±0.40 < 4.2 
   Amplitude(mv) 7.0±3.0 8.10±2.62 >4.4 
   Nerve Conduction 
Velocity (NCV)(m/s) 
57.7±4.9 58.52±3.76 >49 
   F wave latency(ms) - 31 <31 
  SNC Latency(ms) 2.84±0.34 3.06±0.41 <3.5 
   Amplitude(μv) 38.5±15.6 8.91±4.48 >20 
   NCV(m/s) 56.2±5.8 45.45±9.4 >52 
2 Ulnar N. MNC Latency(ms) 2.59±0.39 2.59±0.40 <3.4 
   Amplitude(mv) 5.7±2.0 8.51±2.03 >6.0 
   NCV(m/s) 58.7±5.1 61.45±5.73 >49 
   F wave latency(ms) - 31 <32 
  SNC Latency(ms) 2.54±0.29 2.83±0.40 <3.0 
   Amplitude(μv) 35.0±14.7 5.54±2.37 >15 
   NCV(m/s) 54.8±5.3 54.17±6.10 >52 
3 Peroneal N. MNC Latency(ms) 3.77±0.86 4.55±0.59 <5.8 
   Amplitude(ms) 5.1±2.3 4.23±1.61 >2.0 
   NCV(m/s) 48.3±3.9 46.54±4.4 >42 
   F wave latency(ms) - 61 <58 
4 Tibial N. MNC Latency(ms) - - <6.5 
   Amplitude(ms) - - >3.0 
   NCV(m/s) - 48.3±4.5 >41 
   F wave latency(ms) _ 61 <59 
5 Sural N. SNC Latency(ms) - - <4.4 
   Amplitude(μv) - 18.0±10.5 >6 
   NCV(m/s) - 50.9±5.4 >42 
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Axonal Loss 
Axonal loss reduces SNAP and CMAP amplitudes because they represent the 
summed activity of action potentials. SNAP amplitude is very sensitive to sensory axon 
loss because there is no compensatory collateral reinnervation. The SNAP originates from 
~2000 of the larger diameter nerve fibers (>9 μm in diameter) and amplitude falls rapidly 
with fiber loss (50% amplitude loss with 50% fiber loss) and is unobtainable with surface 
recording when ~75% of large fibers lost [36]. However, smaller diameter fibers may 
remain visible on nerve biopsy. CMAP will be insensitive to mild degrees of motor axon 
loss because of collateral reinnervation. In slowly progressive disorders, >50—80% of 
motor nerve fibers can he lost before CMAP amplitude falls below lower limit of normal 
[27]. Axonal pathology affects conduction velocity measurements (reflected in distal 
latency, F-wave latency and conduction velocity) in proportion to the number of large 
fibers lost. Surviving axons will conduct a normal velocities and with normal temporal 
dispersion. 
Conduction Block 
Conduction block represents failure of nerve fiber action potentials to conduct 
beyond a certain point along the axon. This implies that nerve conduction along the fiber 
is normal on either side of the block. Conduction block can be at a specific site along the 
nerve (focal conduction block) or at multiple sites along the nerve (multifocal conduction 
block). Not all fibers in a nerve may be affected (partial vs. complete conduction block). 
Electrodiagnostic features of focal conduction block are normal conduction distal to the 
block (normal response amplitude), abnormal conduction across the block (reduced 
response amplitude), and normal conduction proximal to the block (no further reduction 
of response amplitude). The magnitude of these changes will vary depending upon how 
many fibers in the nerve are blocked.  
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Table:  Electrodiagnostic Criteria to Distinguish Focal Conduction Block from 
Abnormal Temporal Dispersion in Motor Nerves 
 CMAP negative 
peak amplitude 
CMAP negative 
peak area 
CMAP negative 
peak duration 
1.Conduction block <50% <50% ≤ 30% 
2.Conduction block 
and/or abnormal 
temporal dispersion 
<50% <50% >30% 
 
3.Abnormal temporal 
dispersion 
<50% >50% >30% 
 
 
NEEDLE EMG 
Needle EMG is an adjunct to nerve conduction studies, and provides data on: (1) 
the presence of motor axon damage, (2) localization of lesions within the peripheral 
nervous system and (3) an estimate of the chronicity of motor denervation. 
Presence of Motor Axonal Damage 
The number of axons that need to be damaged before changes in the clinical 
examination or CMAP amplitude are apparent varies with the time course of axonal loss. 
In acute and ongoing disorders, the process of reinnervation will not be able to keep up 
with the rate of denervation, and clinical and CMAP changes will become apparent 
relatively early on. In very chronic disorders, the process of reinnervation has sufficient 
time to reach high capacity, and will be less apparent. Abnormal spontaneous activity 
(positive sharp waves and fibrillation potentials) represents discharges of single muscle 
fibers. These potentials represent muscle fiber membrane hypersensitivity due to 
denervation, and are very sensitive indicator of denervation. Other needle EMG findings 
focus on the MUAP, and in neuropathic conditions findings include reduced MUAP 
recruitment, increased amplitude, and increased number of phases and turns. 
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Localization of Axonal Damage 
Nerve conduction studies are most suitable for the study of distal muscles, 
whereas needle EMG allows assessment of almost any muscle. This allows precise 
localization of axonal damage to nerve roots, the plexus or single nerves. 
Chronicity 
Needle EMG also can provide information on the rate of axonal loss. In acute and 
ongoing processes (recent denervation), fibrillation potentials tend to be large in 
amplitude (>500 μV). They become smaller as the period between the nerve lesion and 
the study increases, and may remain of vary small size (<100μV) indefinitely [37]. 
Accordingly, a pattern of large fibrillation potentials suggests a recent or ongoing process, 
whereas a pattern of small fibrillation potentials suggests an old or very slowly 
progressive(chronic) process. Denervated muscle fibers atrophy, and with recent 
reinnervation, the slower conduction velocity of small diameter muscle fibers contribute 
to the complexity of MUAPs (polyphasia and polyturns) [38]. With time, reinnervated 
muscle fibers increase in diameter and motor units become simplified (fewer phases and 
turns) because of greater temporal dispersion of action potentials making up MUAPs. In 
static conditions, or slowly progressive conditions, motor unit recruitment will be 
reduced, MUAP amplitude will be high, but waveforms will be relatively simple [39]. 
DEMYELINATING POLYNEUROPATHIES 
Identifying demyelinating pathology can be difficult, particularly with chronic 
neuropathies. Nerve biopsy is invasive and is not sensitive for primary demyelination and 
electrodiagnostic testing, in particular nerve conduction studies, is the most useful 
diagnostic tool. Sets of nerve conduction criteria have been proposed to distinguish 
primary demyelination but even with acute inflammatory demyelinating 
polyradiculoneuropathy (AIDP), whose unique time course helps narrow the differential 
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diagnosis, only 50% fulfilled criteria when studied within the first two weeks of 
symptoms. Classic chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) 
is characterized by symmetric proximal and distal motor and sensory nerve involvement 
[40], but other forms of Chronic demyelinating neuropathies are distinguished, including 
those with predominant distal nerve involvement [41], asymmetric nerve involvement 
[42], predominant sensory nerve involvement [43] predominant cranial nerve 
involvement[44]or focal motor nerve conduction block with and without sensory nerve 
involvement [45]  
Electrodiagnostic Criteria for Demyelination 
AIDP and CIDP are the most common examples of multifocal demyelinating 
polyneuropathies. Findings on motor nerve conduction studies supportive of 
demyelinating neuropathies include the following: (i)slowed conduction demonstrated by 
substantially prolonged distal latencies, reduced conduction velocities, and prolonged F- 
and H-wave latencies; (ii) greater degree of phase cancellation and (iii) sites of focal 
conduction block (away from common entrapment sites) demonstrated by reduced CMAP 
amplitude to stimulation proximal to the block with no prolongation of the negative peak 
duration. Secondary axonal damage also occurs with demyelinating pathology and needle 
EMG abnormalities are common in AIDP and CIDP [46] 
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Table: Electrodiagnostic Criteria to Distinguish Primary Demyelinating Pathology 
from Primary Axonal Pathology in Motor Nerves 
Factors Electrodiagnostic evidence 
supportive of primary 
demyelinating neuropathy 
Electrodiagnostic evidence 
supportive of primary axonal 
neuropathy 
Distal CMAP 
amplitude 
Mild to moderate reduction Normal to moderate reduction 
Conduction block 
 
Present (proximal-to distal  
CMAP amplitude ratio <0.50) 
Absent (proximal-to distal  
CMAP amplitude ratio >0.50) 
Temporal 
dispersion 
 
Abnormal (proximal-to-distal  
CMAP negative duration 
<0.75) 
Normal (proximal-to-distal  
CMAP negative duration 
>0.75) 
Abnormal (distal negative 
CMAP  
duration >9 ms) 
Normal (distal negative CMAP  
duration <9 ms) 
 
Distal latency 
 
Moderately to markedly 
prolonged 
(>125% ULN) 
Normal to mildly prolonged 
(<125% ULN) 
 
Conduction 
velocity 
 
Moderately  to markedly slowed 
(<75% LLN) 
Normal to mildly slowed 
(>75% LLN) 
F-wave latency 
 
Moderately to markedly 
prolonged (>125% ULN) 
Normal to mildly prolonged 
(<125% ULN) 
Needle EMG Mild to moderate denervation  Mild to severe denervation 
 
Sensory Nerve Conduction Studies in Demyelinating Neuropathies 
Sensory nerve studies are less useful than motor nerve studies because responses 
are frequently absent, which do not distinguish between primary demyelination and 
axonal loss. However, a pattern of an abnormal median is more common in demyelinating 
neuropathies than in mixed demyelinating and axonal neuropathies [46]. 
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AXONAL POLYNEUROPATHIES 
Primary axonal neuropathies are common and generally follow a length dependent 
pattern [47]. Findings expected on nerve conduction studies for axonal loss include the 
following: (i) reduced or absent motor and sensory responses, (ii) minimally slowed 
conduction, and (iii) evidence for neuropathic denervation on needle EMG [48]. 
Abnormalities will be more severe in lower extremities, with SNAP responses more 
affected than CMAP responses (due to collateral reinnervation). Axonal loss may be 
severe, but will have a modest effect on nerve conduction velocity. Needle EMG findings 
include abnormal spontaneous activity (positive waves and fibrillation potentials) and 
MUAPs show reduced recruitment and increased amplitude.  
MIXED AXONAL AND DEMYELINATING POLYNEUROPATHIES 
CIDP will include secondary axonal loss leading to reduced or absent CMAP 
responses. Diabetes mellitus is the most common cause of distal symmetric 
polyneuropathies with mixed axonal and demyelinating features. HIV infection may 
cause similar pattern. 
SMALL FIBER NEUROPATHIES 
Small fiber neuropathies are clinically defined by symptoms of painful 
paresthesias in a distal distribution [49]. Sensory and motor responses in the legs are 
frequently normal, and when abnormal, sensory responses are reduced or absent [50]. The 
diagnosis of small fiber involvement is confirmed by nerve biopsy showing reduced 
numbers of unmyelinated fibers, or by skin biopsy showing reduced intraepidermal nerve 
fiber density.  
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Materials and Methods 
 
 
Study Design 
This study is a cross sectional study. 
Study period 
This study was conducted during the period from January 2009 to December 
2009, for 1 year. This Study was done in the Department of Neurology, Tirunelveli 
Medical college Hospital, Tirunelveli. 
Patient Selection:  
Patients attending the out patient department of Anti Retroviral Therapy (ART) 
Centre at Tirunelveli Medical College Hospital, Tirunelveli were taken for the study. 
Patients already diagnosed as HIV positive and on Highly Active Anti Retroviral Therapy 
(HAART) only were selected for the study. Both male and female patients were taken for 
the study.  Study was done with the consent of the patients. 
Inclusion criteria: 
1. Patients who were seropositive for HIV infection and registered with ART centre 
of Tirunelveli Medical College Hospital. 
2. Patients on HAART. 
3. Both symptomatic and asymptomatic patients. 
4. Patients were selected irrespective of stage of the disease, CD4 count and duration 
of the HIV illness. 
Exclusion criteria: 
1. HIV seropositive patients who were not on HAART at the time of the study. 
2. Patients with other systemic illness like diabetes mellitus, renal disease, thyroid 
disease, nutritional anaemia, Hansen’s disease. 
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3. History suggestive of collagen vascular diseases, recent Chikunkunya fever or any 
other viral illness or jaundice. 
4. Patients who regularly consume alcohol of > 40 units/week. 
All the patients were analysed for, 
1. Symptoms of peripheral neuropathy like numbness, tingling, burning pain, pins & 
needles sensation, muscle thinning, weakness, cramps and other relevant 
symptoms. 
2. If symptoms present, onset and duration of symptoms, whether present before or 
after starting Anti Retroviral Therapy is noted. 
3. Detailed neurological examination for the presence of signs of peripheral 
neuropathy like diminished touch, pain, temperature and impaired vibration and 
joint position sensation and muscle wasting, weakness and diminished or absent 
reflexes. 
4. Routine biochemical investigations and complete hemogram to rule out other 
systemic illness. 
5. Electrophysiological Study: All the patients were encouraged to undergo nerve 
conduction study. As many patients refused, study was done in all symptomatic 
patients and counseling given to remaining asymptomatic patients and at last 5 
patients, who were not having symptoms, were willing to undergo 
electrophysiological study. Totally 30 patient underwent nerve conduction study. 
The nerve conduction studies were performed with surface recording for sensory 
and motor nerves. Sensory nerve conduction studies of the sural, ulnar and median   
nerves were performed orthodromically. Distance was measured from the 
stimulating cathode to the recording cathode.  Measurements included (1) 
amplitude, in microvolts; (2) latency, in milliseconds; and (3) conduction velocity 
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(CV), in meters per second. For motor nerve conduction studies, supramaximal 
nerve stimulation was applied transcutaneously to a distal and proximal segment 
of the  tibial, peroneal, median and ulnar nerves. The compound muscle action 
potential (CMAP) was recorded with surface disk electrodes. Measurements of the 
CMAP taken by cursor include (1) amplitude, in millivolts; (2) latency, in 
milliseconds; and (3) conduction velocity, in meters per second. F-wave latencies 
were obtained from the median, ulnar, peroneal and tibial motor nerves by 
recording the minimum latency of 10 responses; at least 10 supramaximal stimuli 
were applied before it was concluded that F-waves were absent. 
Electrophysiological diagnosis of peripheral neuropathy was done with standard 
reference values. [60, 63, 64] 
6. The diagnosis of peripheral neuropathy was based on the following criteria: (1) 
symptoms of peripheral neuropathy (like pain, paresthesias, numbness or 
weakness in the extremities), (2) neurologic signs (including absent or diminished 
ankle and or knee reflexes; and reduction of vibratory, pain, or temperature 
sensation), (3) electrophysiological evidence.  
 
 
 
 
 
 
 
Observations and Results 
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1. DATA OF STUDY GROUP 
Epidemiological data 
Total number of patients in our study group is 60. Among them males were 
33(55%) and females were 27 (45%).  
Ta
bl
e 
1.
1 MALE FEMALE TOTAL 
33 (55%) 27 (45%) 60 (100) 
 
Age Group: Patients were in varying age groups. Minimum of 21 years to 
maximum of 54 years. Males were aged from 28 to 54 yrs and females were from 
21 to 52 yrs. 
 
Ta
bl
e 
1.
2 
GROUP 
MINIMUM 
AGE 
(YEARS) 
MAXIMUM 
AGE 
(YEARS) 
RANGE 
(YEARS)
Total study 
group 
21 54 21-54 
Male 28 54 28-54 
Female 21 52 21-52 
 
More number of patients were in 31-40 yrs (55%) and 21-30 yrs (21.7%) 
age group. 
   
T
ab
le
 1
.3
 
AGE GROUP MALE FEMALE TOTAL 
21-30 Yrs 4 (12.1%) 9(33.3%) 13 (21.7%) 
31-40 Yrs 19 (57.6%) 14(51.9%) 33(55.0%) 
41-50 Yrs 8(72.7%) 3(11.1%) 11(18.3%) 
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51 Yrs & Above 2(6.1%) 1(3.7%) 3 (5.0%) 
TOTAL 33 (100%) 27 (100%) 60 (100%) 
 
Clinical data 
1. Clinical Staging: Patients were staged according to WHO staging system and they 
were in various stages. More number of patients were in stages III & IV (65%) compared 
to stages I & II (35%) 
T
ab
le
 1
.4
 
STAGE 
NUMBER OF 
PATIENTS 
I 19 (31.7%) 
II 2(3.3%) 
III 32(53.3%) 
IV 7 (11.7%) 
 
Most of the male patients were in stages III & IV and most of the female patients were in 
stages I & II. 
T
ab
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 1
.5
 
STAGE MALE FEMALE TOTAL 
I 3 (9.1%) 16 (59.3%) 19 (31.7%) 
II 1 (3.0%) 1 (3.7%) 2 (3.3%) 
II 25 (75.8%) 7 (25.9%) 32 (53.3%) 
IV 4 (12.1%) 3 (11.1%) 7 (11.7%) 
TOTAL 33 (100%) 27 (100%) 60 (100%) 
 
Chi-square: 18.750;   df: 3        p-value < 0.0001 
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Figure: 1. Clinical Stage and Sex - Multiple Bar Chart 
 
2. Duration of HAART:  The duration of  HAART varied from 1 – 48 months 
with mean of 23 months. Those who were on HAART of <12 months were 20, 13-
24 months were 19, in 25-36 months were 12, >37 months were 9. Among these, 
more number of patients 39 (65%) were taking HAART of less than 24 months. 
 
Ta
bl
e 
1.
6 
DURATION of 
HAART 
MALE FEMALE TOTAL 
0-12 Months 10 (30.3%) 10 (37.0%) 20 (33.3%) 
13-24 Months 11 (33.3%) 8 (29.6%) 19 (31.7%) 
25-36 months 5 (15.2%) 7 (25.9%) 12 (20.0%) 
More than 36 
Months 
7 (21.2%) 2 (7.4%) 9 (15.0%) 
TOTAL 33 (100%) 27 (100%) 60 (100%) 
 
Chi-square: 3.015       p-value = 0.398. 
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3. CD4 count: CD4 count was done twice in ART clinic. One at time of diagnosis 
of HIV seropositivity and one done recently, that is while undergoing this study. 
Patients having CD4 < 200 are 31(51.7%) > 200 are 29 (48.3%).  
T
ab
le
 1
.7
 CD4 < 200 CD4 > 200 TOTAL 
31 (51.7%) 29 (48.3%) 60 (100%) 
 
In male patients, those having CD4 less than 200 are 24/33, more than 200 
are 9/33 and they were in the range of 35-950. In females those having CD4 less 
than 200 are 7/27 and more than 200 are 20/27 and they were in the range of 206-
1039. Most (72.7%) of the male patients were having CD4 count less than 200. 
T
ab
le
 1
.8
 
CD4 COUNT 
(per μl) 
MALE FEMALE TOTAL 
CD4 < 200 24 (72.7%) 7 (25.9%) 31 (51.7%) 
CD4 > 200 9 (27.3%) 20 (74.1%) 29 (48.3%) 
TOTAL 33 (100%) 27 (100%) 60 (100%) 
 
Chi-square: 13.025;   df: 1        p-value < 0.0001 
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4.Treatment Regimen:  
Patients were on various treatment regimens as follows: 
REGIMENS OF ART TREATMENT 
T
ab
le
 1
.9
 
REGIMEN FREQUENCY PERCENTAGE 
 On ATT 1 1.7 
 
SLE ATT 1 1.7 
SLE SLN 4 6.7 
SLE ZLN 6 10.0 
SLN 12 20.0 
SLN SLE 1 1.7 
SLN ZLN 8 13.3 
ZLE SLN 1 1.7 
ZLN  SLN 1 1.7 
 
ZLE 1 1.7 
ZLE ATT 1 1.7 
ZLE ZLN 8 13.3 
ZLN 15 25.0 
 Total 60 100.0 
   
Among them, patients in stavudine group were 56.7% and non-stavudine group were 
41.7% and 1 patient was taking ATT at the time of our study. 
T
ab
le
 1
.1
0 STAVUDINE GROUP 
NON-STAVUDINE 
GROUP 
34 (56.7%) 25 (41.7%) 
 
Both males and females were nearly equally present in both groups. 
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Figure: 2. Treatment Group- Pie Chart 
 
T
ab
le
 1
.1
1 
REGIMEN MALE FEMALE TOTAL 
ATT 1 (3.0%) 0 (0.0%) 1 (1.7%) 
STAVUDINE 17 (51.5%) 17 (63.0%) 34 (56.7%) 
NON-
STAVUDINE 
15 (45.5%) 10 (37.0%) 25 (41.7%) 
TOTAL 33 (100%) 27 (100%) 60 (100%) 
 
5. Distribution of Symptoms: Among the total number of 60 patients, 23 (38.3%) 
patients had symptoms of peripheral neuropathy and remaining were asymptomatic. 
Ta
bl
e 
1.
12
 SYMPTOMATIC ASYMPTOMATIC 
23 (38.3%) 37 (61.7%) 
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T
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le
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.1
3 
SEX 
AGE 
(years) 
DURATION 
(months) 
CD4 COUNT 
(perμl) 
FEMALE 
N 27 27 27 
Minimum 21 2 206 
Maximum 52 42 1039 
Mean 33.22 19.59 508.70 
Std. 
Deviation 
7.708 11.011 220.815 
MALE 
N 33 33 33 
Minimum 28 1 35 
Maximum 54 48 950 
Mean 38.00 23.09 351.58 
Std. 
Deviation 
5.590 14.894 250.482 
TOTAL 
N 60 60 60 
Minimum 21 1 35 
Maximum 54 48 1039 
Mean 35.85 21.52 422.28 
Std. 
Deviation 
6.991 13.298 248.456 
 
2.  DATA OF PERIPHERAL NEUROPATHY GROUP 
Among the study group of 60 patients, 26 were having evidence of peripheral 
neuropathy 
T
ab
le
 2
.1
 
Peripheral 
Neuropathy 
PRESENT 
Peripheral 
Neuropathy 
ABSENT 
TOTAL 
26 34 60 
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Figure: 3. Peripheral Neuropathy prevalence- Pie Chart 
 
Among the 26 patients with Peripheral Neuropathy, those with Distal 
Symmetrical Polyneuropathy (DSP) were 18 (69.2%), Distal Sensory 
Polyneuropathy (Distal Symmetric  Polyneuropathy with only sensory findings) 
were 2 (7.7%), Chronic Inflammatory Demyelinating Polyradiculoneuropathy 
(CIDP) were 5 (19.2%) and Mononeurits Multiplex was 1 (3.8%).  
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PERIPHERAL NEUROPATHY –
TOPOGRAPHICAL AND CLINICAL TYPES 
NUMBER PERCENTAGE
CIDP 5 8.3 
Distal Sensory Polyneuropathy 2 3.3 
Distal Symmetric  Polyneuropathy 18 30.0 
Mononeuritis Multiplex 1 1.7 
Peripheral Neuropathy - ABSENT 34 56.7 
TOTAL 60 100.0 
 
1. Sex and Peripheral Neuropathy: Among the 26 patients with peripheral 
neuropathy, 17 (65.4%) were males and 9 (34.6%) were females. Common type 
seen in both males and females is distal symmetric polyneuropathy. 
 
T
ab
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.3
 
Topographical and 
clinical types of 
peripheral neuropathy  
MALE FEMALE TOTAL 
CIDP 
4 
(23.5%) 
1 (11.1%) 5 (19.3%) 
Distal Sensory 
Polyneuropathy 
2 
(11.8%) 
0 (0.0%) 2 (7.7%) 
Distal Symmetric  
Polyneuropathy 
10 
(58.8%) 
8 (88.9%) 18 (69.2%) 
Mononeuritis Multiplex 1 (5.9%) 0 (0.0%) 1 (3.8%) 
TOTAL 
17 
(100%) 
9 (100%) 26 (100%) 
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Figure: 4. Sex and Peripheral Neuropathy Types – Multiple Bar Chart 
 
2. Age & Peripheral Neuropathy: Among the 26 patients with PN, they were in 
different age groups: 21-30yrs – 5 (19.2%), 31-40yrs – 13 (50%), 41-50yrs – 5 
(19.2%), >51yrs – 3 (11.5%). More number of patients belonged to 31-40 years 
age group. 
 
   
 T
ab
le
 2
.4
 
AGE 
GROUP 
TOTAL 
Peripheral 
Neuropathy 
– PRESENT 
Peripheral 
Neuropathy - 
ABSENT 
Percentage 
of 
peripheral 
neuropathy
21-30 Yrs 13(21.7%) 5 (19.2%) 8 (23.5%) 38.5 % 
31-40 Yrs 33 (55.0%) 13 (50.0%) 20 (58.8%) 39.4 % 
41-50 Yrs 11 (18.3%) 5 (19.2%) 6 (17.6%) 45.5 % 
51 Yrs & 
Above 
3 (5.0%) 3 (11.5%) 0 (0.0%) 
100 % 
TOTAL 60  26  34   
 
Chi-square: 4.277       p-value: 0.233. 
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3. Stage of disease and Peripheral Neuropathy: More number of patients (19 out 
of 26 or 71.1%) were in stages III & IV, compared to stages I & II (7 out of 26 or 
28.9%). In the study group, 39/60 were in stages III & IV and 21/60 were in stages 
I & II. Among the 39 patients of stage III & IV, 19 (48.7%) suffers from peripheral 
neuropathy and among the 21 patients of stage I & II, 7 suffers from peripheral 
neuropathy.  
T
ab
le
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STAGE 
Peripheral 
Neuropathy – 
PRESENT 
Peripheral 
Neuropathy - 
ABSENT 
TOTAL 
I 6 (23.1%) 13 (38.2%) 19 (31.7%) 
II 1 (3.0%) 1 (2.9%) 2 (3.3%) 
III 15 (55.7%) 17 (50.0%) 32 (53.3%) 
IV 4 (15.4%) 3 (8.8%) 7 (11.7%) 
TOTAL 26  34 60 
 
Chi-square: 1.812        p-value = 0.612 
 
4. Duration of HAART and Peripheral Neuropathy: Among the 26 patients, 
those who were on HAART of 0-12 months are 12 (46.2%), 13-24 months are 6 
(23.1%), 25-36 months are 4 (15.4%) and more than  36  months are 4 (15.4%). 
Among the 39 patients of less than 24 months, 18 (46.2%)suffers from peripheral 
neuropathy and among the 21 patients of  more than 24 months, 8 (38.1%)suffers 
from peripheral neuropathy. 
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T
ab
le
 2
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Duration of 
HAART 
Total no. of 
patients 
Peripheral 
Neuropathy 
- PRESENT 
Peripheral 
Neuropathy 
- ABSENT 
 
percentage 
0-12 Months 20 (33.3%) 12 (46.2%) 8 (23.2%) 60% 
13-24 Months 19 (31.7%) 6 (23.1%) 13 (38.2%) 31.6% 
25-36 months 12 (20.0%) 4 (15.4%) 8 (23.5%) 33.3% 
> 36 Months 9 (15.0%) 4 (15.4%) 5 (14.7%) 44.4% 
TOTAL 60 26  34   
       
Chi-square: 3.825       p-value = 0.281 
 
Figure: 5. Duration of HAART and Peripheral Neuropathy – Component Bar 
Chart 
5. CD4 count and Peripheral Neuropathy: Those patients with peripheral 
neuropathy with CD4 < 200 were 9 (34.6%), and > 200 were 17 (65.4%). In total 
study group, patients with CD4 < 200 were 31 (51.7%) and > 200 were 29 
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(48.3%). This shows no increased risk of developing PN for those patients with 
less CD4 count. But it is not statistically significant. 
T
ab
le
 2
.7
 CD4 < 200/μl CD4 > 200/μl 
9 (34.6%) 17 (65.4%) 
 
6. Regimen group and Peripheral Neuropathy: Among the 26 patients with 
peripheral neuropathy, 16 (61.5%) were in stavudine group and 1 was taking ATT 
and remaining 9 (34.6%) were in non-stavudine group.  
T
ab
le
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REGIMEN GROUP 
Peripheral 
Neuropathy - 
PRESENT 
Peripheral 
Neuropathy - 
ABSENT 
TOTAL 
ATT 1 (3.8%) 0 (0.0%) 1 (1.7%) 
STAVUDINE 16 (61.5%) 18 (52.9%) 34 (56.7%) 
NON-STAVUDINE 9 (34.6%) 16 (47.1%) 25 (41.7%) 
TOTAL 26  34 60 
 
Chi-square: 2.047; df: 2;        p-value = 0.359. 
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Figure: 6. Regimen Group and Peripheral Neuropathy – Multiple Bar Chart 
 
Among these 26 patients with peripheral neuropathy, when correlating duration of 
HAART  with regimen and CD4 cell count, it shows the following results: 
 
T
ab
le
 2
.9
 
 
Duration 
of HAART 
No. of peripheral neuropathy patients 
Regimen CD4 cell count/μl  
On 
Stavudine  
On Non-
Stavudine  
Less 
than 
200 
More 
than 200 
Total 
0 – 12 
months 
5 7 4 8 12 
13 – 24 
months 
4 2 3 3 6 
25 – 36 
months 
3 1 2 2 4 
> 36 
months 
4 Nil 2 2 4 
Total 16 10 11 15 26 
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T
ab
le
 2
.1
0 
Duration of 
HAART 
Total no. 
patients 
Stavudine 
users (A) 
Peripheral 
neuropathy 
present in (A) 
Non-
stavudine 
users (B) 
Peripheral 
neuropathy 
present in 
(B) 
0-12 months 20 10 5 (50%) 10 7 (70%) 
13-24 months 19 10 4 (40%) 9 2 (22.2%) 
25-36 months 12 8 3 (37.5%) 4 1 (25%) 
> 36 months 9 6 4 (66.7%) 3 Nil  
Total 60 34 16 (47.1%) 26 10 (38.5%) 
 
T
ab
le
 2
.1
1 
Stage of 
disease 
Stavudine 
users(A) 
Peripheral 
neuropathy 
present 
among(A) 
Non-
stavudine 
users(B) 
Peripheral 
neuropathy 
present 
among(B) 
I & II 10 4 (40%) 11 4 (36.4%) 
III 18 9 (50%) 14 6 (42.9%) 
IV 6 3 (50%) 1 0 
Total 34 16 26 10 
 
7. Analysis of symptomatic patients 
Among the 26 patients with peripheral neuropathy, 23 patients (88.5%) had 
both symptoms and signs of peripheral neuropathy and 2 patients, showed signs of 
peripheral neuropathy during clinical examination and nerve conduction study also 
confirmed this. 
T
ab
le
 2
.1
2 Symptoms and 
signs present 
Only signs 
present 
Only electrophysiological 
evidence  present 
23/26 (88.5%) 2/26 (7.7%) 1/26 (3.8%) 
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2
23
34
1
only signs present
both symptoms and signs
present
peripheral neuropathy
absent
only EP evidence present
 
 
Figure: 7. Distribution of symptoms and signs – Pie Chart 
 
Patients, who didn’t have either symptoms or signs of peripheral neuropathy, were 35. 
Among them 5 underwent electrophysiological analysis. One of them showed 
electrophysiological evidence of peripheral neuropathy. 
T
ab
le
 2
.1
3 Total No. of 
patients 
Not having either 
symptoms or signs 
(B) 
Underwent 
Electrophysiology 
study among (B) 
Electrophysiology 
evidence of 
Peripheral 
Neuropathy seen in 
60 35 5 1 
 
All the symptomatic patients had electrophysiological evidence of 
peripheral neuropathy and this is statistically significant as p-value is < 0.0001. 
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T
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le
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.1
4 
SYMPTOMS 
Peripheral 
Neuropathy – 
PRESENT 
Peripheral 
Neuropathy - 
ABSENT 
TOTAL 
PRESENT 23 (88.5%) 0 (0.0%) 23 (38.3%) 
ABSENT 3 (11.5%) 34 (100%) 37 (61.7%) 
TOTAL 26  34 60 
 
Chi-square:  48.773            p-value <0.0001 
Sensitivity: 88.5%; Specificity: 100%;  PPV: 100%;  NPV: 91.9% 
 
8. Analysis of Symptoms: Frequent symptoms we encountered were numbness 
(17 patients), tingling (8 patients) and electric shock-like sensation (5 patients) and 
less frequent symptoms were burning pain (3 patients) and pins and needles 
sensation(5 patients). Some patients (4 patients) had cramps in both legs. Only few 
patients (2 patients) showed weakness.         
T
ab
le
 2
.1
5 
SYMPTOM No. OF PATIENTS 
Numbness 17 
Tingling 8 
Pins & needles 5 
Burning pain 3 
Both tingling & burning 4 
Cramps 4 
Weakness 2 
 
Most of the patients showed symptoms in lower limbs (20 patients). Only in 5 
patients symptoms were present in both upper and lower limbs.   
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T
ab
le
 2
.1
6 
SYMPTOMS No. OF PATIENTS 
Only in lower limbs 20 
Both lower & upper limbs 5 
 
9. Sensory signs: Sensory signs, seen in our study were diminished vibration, 
touch, pain and temperature in that order. Mostly these were present below the 
ankles and only in some patients below the knees. In few patients, especially in 
CIDP group signs were present in hands.  In 17 patients all modalities like 
vibration, touch, pain and temperature were lost in lower limbs. In 8 patients only 
vibration impairment was seen. In 3 patients sensory signs (impairment of 
vibration) were present in hands. 
Ta
bl
e 
2.
17
 SENSORY IMPAIRMENT NO. OF PATIENTS 
Impairment of vibration, touch, pain 
and temperature 
17 
Only impairment of vibration 8 
 
10. Motor signs: Ankle jerk was diminished in 6 patients and absent in 11 
patients. 4 patients had diminished knee jerk. Weakness in ankle dorsiflexion and 
plantar flexion were seen in 2 patients, weakness in extension of great toe was 
present in 4 patients and in 7 patients toe-grip was weak. Wasting seen in intrinsic 
foot muscles in 3 patients. In upper limbs, signs were not seen except in patients 
with CIDP (Chronic Inflammatory Demyelinating Polyneuropathy) who showed 
both sensory and motor features. Like wise CIDP patients had both proximal and 
distal weakness in lower limbs. 
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T
ab
le
 2
.1
8 
SIGNS NO. OF PATIENTS 
Diminished ankle jerk 6 
Absent ankle jerk 11 
Diminished knee jerk 4 
Weakness of ankle dorsiflexion 
and plantar flexion 
2 
Weakness in extension of great toe 4 
Toe grip weakness 7 
Wasting in extremities 3 
 
11. Electrophysiology 
Nerve conduction study was done totally in 30 patients. Among them, 
electrophysiological evidence of peripheral neuropathy was seen in 26 patients. 
Predominant pattern seen was mixed neuropathy (both axonal and demyelination) in 18 
patients. Among the 5 patients with CIDP, 1 patient had features of both axonal and 
demyelination pattern and others had predominant demyelination pattern. 3 patients had 
only axonal pattern. Both motor and sensory neuropathy were seen in 24 patients and 
only sensory neuropathy was seen in 2 patients.  
T
ab
le
 2
.1
9 
PATHOLOGICAL PATTERN 
OF NEUROPATHY 
NO. OF PATIENTS 
Axonal 3 
Demyelinating 5 
Both axonal & demyelination 18 
 
Distribution of Neuropathy: In 13 patients electrophysiological evidence of peripheral 
neuropathy was seen in both upper limbs and lower limbs. In remaining 13 patients only 
in lower limbs peripheral neuropathy was present. In patients with distal symmetric 
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polyneuropathy, electrophysiological evidence was predominantly seen in lower limbs 
(13 patients) and in remaining 7 patients was seen both in upper limbs and lower limbs. 
T
ab
le
 2
.2
0 
Electrophysiological evidence of 
peripheral neuropathy seen in 
No. of patients 
Only in lower limbs 13 
Both upper & lower limbs 13 
 
The following table analyses the correlation between the peripheral neuropathy 
and age of the patients, duration of HAART and CD4 count. 
 
T
ab
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.2
1 
PERIPHERAL NEUROPATHY
AGE 
(years) 
DURATION of 
HAART(months) 
CD4 COUNT 
PRESENT 
N 26 26 26 
Minimum 21 1 35 
Maximum 54 48 950 
Mean 37.62 19.15 367.85 
Std. Deviation 7.874 14.603 247.253 
ABSENT 
N 34 34 34 
Minimum 23 2 66 
Maximum 46 48 1039 
Mean 34.50 23.32 463.91 
Std. Deviation 6.006 12.117 244.811 
TOTAL 
N 60 60 60 
Minimum 21 1 35 
Maximum 54 48 1039 
Mean 35.85 21.52 422.28 
Std. Deviation 6.991 13.298 248.456 
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The following table shows the statistical analysis of peripheral neuropathy with various 
factors. 
T
ab
le
 2
.2
2 
FACTOR 
Peripheral 
Neuropathy – 
PRESENT 
(N= 26) 
Peripheral 
Neuropathy – 
ABSENT 
(N= 34) 
ODDS 
RATIO 
Chi- 
square 
p-
value 
AGE > 36 Yrs 19 (73.1%) 15 (44.1%) 3.48 5.032 0.025 
SEX -MALE 17 (65.4%) 16 (47.1%) 1.37 1.999 0.157 
DURATION 
≥ 22 MONTHS 
11 (42.3%) 19 (55.9%) 0.58 1.086 0.297 
SYMPTOM 
OF 
PERIPHERAL 
NEUROPATHY 
23 (88.5%) 0 (0.0%) 21.3 48.77 0.000 
CLINICAL 
STAGE –III&IV 
19 (73.1%) 20 (58.8%) 1.24 1.321 0.251 
CD4 COUNT 
≤ 200 
12 (46.2%) 19 (55.9%) 0.67 0.558 0.455 
 
increasing age and advanced clinical stages are significantly associated with more 
prevalence of peripheral neuropathy. 
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Discussion 
 
This study is a cross sectional study done to estimate the prevalence and to 
evaluate the risk factors, types and pattern of peripheral neuropathy in HIV infected 
individuals in our region.  
1. Analysis of the study group  
In this study, a survey of variables related to peripheral nerve function in the group 
of HIV-infected individuals in whom nerve conduction studies and several potential 
pathogenetic factors have been systematically studied.  
In our study group, among the total number of 60 patients, 33(55%) were males 
and 27 (45%) were females (Ref. Table 1.1). Patients with varying age group were 
included in our study from 21 years to 54 years.  Males were aged from 28 to 54 yrs and 
females from 21 to 52 yrs. More number of patients were in 31-40 yrs age group (55%) 
followed by 21-30 yrs (21.7%) age group. (Ref. Table 1.3) 
They were in various stages of disease from stage I to stage IV (Ref. Table 1.4, 
1.5) The staging was done based on WHO staging at the time of the diagnosis of the 
disease. There were 19 patients in stage I, 2 patients in stage II, 32 patients in stage III 
and 7 patients in stage IV. More number of the males were in the advanced stages (29 – 
87.9% in stages III & IV) as compared to females (10 – 37.0% in stages III & IV). The 
difference was statistically significant (p- value < 0.0001).   
The duration of the patients on HAART varied from 1 – 48 months with mean of 
23 months (Ref. Table 1.6).  Those who were on HAART of <12 months were 20 
(33.3%), 13-24 months were 19 (31.7%), in 25-36 months were 12 (20.0%), >37 months 
were 9 (15.0%).  
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CD4 count value was taken from medical records and two counts were noted. One 
at the time of diagnosis of HIV seropositivity and another one done recently, that is while 
doing examination. Patients having CD4 < 200 were 31(51.7%) and > 200 were 29 
(48.3%) (Ref. Table 1.7, 1.8). In male patients, those having CD4 less than 200 were 
24/33 (72.7%), more than 200 were 9/33 (27.3%). In females those having CD4 less than 
200 were 7/27 (25.9%) and more than 200 were 20/27 (74.1%).  The males had less CD4 
count as compared to females. The difference is statistically significant (p- value < 
0.0001) 
Patients were on various regimen groups. In the ART centre attached to our 
hospital, 4 types of regimens are followed, which contain 2 NRTIs and 1 NNRTI. The 
following regimens are used. ZLN, ZLE, SLN, SLE (Z – zidovudine, L – lamivudine, S – 
stavudine,  N – nevirapine, E – efavirenz). Among NRTIs lamivudine is compulsorily 
added and either zidovudine (if no anemia) or stavudine (if no PN) is added. Among 
NNRTIs either nevirapine (if no ATT or hepatotoxicity) or efavirenz (if nevirapine 
contraindicated) is used. Some patients who were suffering from PT were started on ATT 
first and then after completing ATT, later started on HAART and in between also if PT is 
detected, HAART stopped and ATT started and HAART restarted later. Totally 23 such 
patients were given ATT at one point of time. Among whom one was presently on ATT 
at the time of our study (Ref. Table 1.9, 1.10, and 1.11).  
Patients who were on stavudine regimen were 34 (56.7%). Remaining were on 
non-stavudine regimen 26 (43.3%). Among the drugs used as HAART, the‘d’ drugs 
(didanosine, zalcitabine, stavudine) are prone to produce neurotoxicity. In our ART centre 
stavudine is used and other 2 drugs are not used. So patients were divided into those on 
stavudine (stavudine group) and not on stavudine (non-stavudine group).  
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2. Analysis of Peripheral Neuropathy Group 
Among the 60 patients under the study, 26 patients were having peripheral 
neuropathy and electrophysiological study confirmed the condition. 
1. Types of Peripheral Neuropathy: Among the 26 patients with peripheral neuropathy 
those with distal symmetrical polyneuropathy (DSP) were 18 (69.2%), distal symmetric 
polyneuropathy with only sensory findings (Distal Sensory Polyneuropathy) were 2 
(7.7%), CIDP were 5 (19.2%) and Mononeuritis Multiplex (MM) was 1 (3.8%) (Ref. 
Table 2.2). Among the inflammatory demyelinating polyneuropathies, both AIDP (acute 
inflammatory demyelinating polyradiculoneuroathy) and CIDP (chronic inflammatory 
demyelinating polyradiculoneuropathy) can occur in HIV infected patients [66]. Acute 
form often presents at the time of HIV seroconversion or primary infection. But we did 
not encounter AIDP though we had 5 patients of CIDP. This may be because of the 
method of patient selection. We selected patients from out patient department of ART 
centre where they come for follow up and getting drugs. Acutely ill AIDP patients could 
have been admitted and treated either in the intensive medical care unit or in the medical 
units. Other types described in text books and literature [66, 74] like progressive 
polyradiculopathy, autonomic neuropathy and mononeuropathy were not seen in our 
study, as noted in other Indian study [68]. 
In our study, distal symmetric polyneuropathy was the common type (76.9%), 
even after exclusion of patients with confounding factors for distal peripheral neuropathy, 
like diabetes mellitus and alcoholism, an observation similar to those described in 
literature [71]. As this distal symmetric polyneuropathy can occur due to HAART as well 
as due to ATT, it needs prospective analysis to find out whether it is drug induced. 
Overall, among the total number of study group of 60 patients, distal symmetric 
polyneuropathy seen in 20 patients (33.3%) similar to described in other series [69]. 
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2. Age & Peripheral Neuropathy: Among the 26 patients with peripheral neuropathy, 
they were in different age groups: 21-30yrs – 5 (19.2%), 31-40yrs – 13 (50%), 41-50yrs – 
5 (19.2%), >51yrs – 3 (11.5%) (Ref. Table 2.4). When comparing this with total study 
population of same age group, prevalence gradually increases from 38.5% to 100%. 
(Ref.Table.2.4). This shows the prevalence increases as age advances as seen in other 
studies [76]. But it is not statistically significant (p- value= 0.233). . An article reviewing 
the impact of aging in HIV infection and its neurological complications [75] explains that 
aging is associated with a higher viral load and immunosenescence, with a decrease in the 
naive subsets of CD4 cells, decreases in T cell proliferative responses and decreased 
ability to respond to novel pathogens, resulting in a potential synergism between HIV 
infection and aging.  
3. Sex and Peripheral Neuropathy: Among the 26 patients with peripheral neuropathy, 
17 (65.4%) were males and 9 (34.6%) were females (Ref. Table 2.3). When comparing 
this with overall study group (60 patients) also males are more affected (17/33 or 51.5%) 
than females (9/27 or 33.3%). That shows peripheral neuropathy more in male patients. 
But statistically it is not significant.  
4. Duration of HAART and Peripheral Neuropathy: Among the 26 patients, those who 
were on HAART of < 24 months are 18 (69.2%), whereas more than > 24 months are 8 
(30.8%) (Ref. Table 2.6). When taking the total study population into account, prevalence 
of peripheral neuropathy gradually decreases from 60% (in 0-12 months duration of 
HAART) to 44.4% (in more than 36 months of HAART) (Ref. Tab.2.6). This indicates 
that longer duration of HAART reduces the chance of developing peripheral neuropathy. 
HAART lessens disease progression, improves immunity, and widens the ratio of 
therapeutic to toxic effects of individual antiretroviral drugs, resulting in a significantly 
lower risk of developing peripheral neuropathy [74]. 
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5. Treatment regimen and Peripheral Neuropathy: Among the 26 patients with 
peripheral neuropathy, 16 (61.5%) were on stavudine regimen and 1 was taking ATT and 
remaining 9 (34.6%) were on non-stavudine regimen. When comparing this with total 
study population of 60 patients, peripheral neuropathy seen in stavudine users is 47.1% 
(16/34) and in non-stavudine user is 36% (9/25) (Ref. Table 2.8). This shows more 
number of peripheral neuropathy in stavudine users. This observation is similar to the 
findings seen in other studies [73]. But it is not statistically significant as p-value is 0.359.  
Another observation is that in all the stages of the disease, peripheral neuropathy is 
slightly more in stavudine users (Ref. Table.2.9, 2.10). This suggests the possibility of 
drug toxicity of the stavudine is an added factor for the development of peripheral 
neuropathy in all the stages.  
Interestingly in less than 12 months duration of HAART, peripheral neuropathy 
patients on stavudine regimen were 5 and on non-stavudine regimen were 5 (excluding 1 
patient on ATT and another one was on ZLE & ATT). That is, at the time of 
seroconversion, peripheral neuropathy seen equally in both stavudine and non-stavudine 
regimen. In 13-24 months duration of HAART, patients on stavudine regimen were 4 and 
on non-stavudine regimen were 2. In 25-36 months duration of HAART, patients  on 
stavudine regimen were 3 and non-stavudine regimen was 1. In more than 36 months of 
HAART, patients on stavudine were 4 and none was on non-stavudine regimen (Ref. 
Table.2.9). This indicates that peripheral neuropathy in the initial period of 
seroconversion may be due to the disease process because irrespective of the type of 
regimen used, peripheral neuropathy was seen and in peripheral neuropathy of later 
period, may be due to drug toxicity, because peripheral neuropathy was seen only in 
stavudine users. This is supported by the evidence that peripheral neuropathy seen in 
more than 36 months of HAART group was associated with increased CD4 count in 2 of 
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4 patients   (Ref. Table2.9). (suggestive of improved immunological status). So peripheral 
neuropathy in that duration of HAART might be due to neurotoxicity of stavudine. 
However, this is a study of small group and this needs to be evaluated with large number 
of patients.     
 6. Stage of disease and Peripheral Neuropathy: More number of patients (19 out of 26 
or 71.1%) were in stages III & IV, compared to stages I & II (7 out of 26 or 28.9%) (Ref. 
Table 2.5). In total number of study group, 39 (out of 60) were in stages III & IV and 21 
(out of 60) were in stages I & II. When comparing these two data,  increased risk of 
developing peripheral neuropathy in advance stages (stage III & IV: 48.7% or 19/39 and 
stages I & II: 33.3% or 7/21), an observation similar to other studies [69].But it is not 
statistically significant in our study (p-value: 0.612). 
7. CD4 count and Peripheral Neuropathy: Those with peripheral neuropathy with CD4 
< 200 are 9 (34.6%), and > 200 are 17 (65.4%) (Ref. Table 2.7). In total study group, 
patients with CD4 < 200 are 31 (51.7%) and > 200 are 29 (48.3%). This shows no 
increased risk of developing peripheral neuropathy for those patients with less CD4 
count. But it is not statistically significant. Peripheral neuropathy patients with CD4 count 
more than 200 suggest that peripheral neuropathy may be due to drug toxicity or other 
underlying conditions as described in literature [9]. 
8. Analysis of symptoms: Frequent symptoms we came across were numbness (17/23), 
tingling (8/23), electric shock like sensation (5/23) with less frequently burning pain 
(3/23), pins and needles (5/23) (Ref table 2.15). Our findings are comparable with those 
reported in previous studies, in which subjective pain was uncommon and usually present 
in more advanced stages [26, 72]. These observations are similar to that reported in other 
studies [69]. Some patients (4) had cramps in both legs, as reported in some other series 
[69], which could be due to motor neuropathy or metabolic or drug related and could not 
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be differentiated. Most (20/25) of the patients had symptoms in lower limbs. Only in 5 
patients, symptoms were present in hands and legs. But electrophysiological study picked 
up the presence of peripheral neuropathy in upper limbs in some patients who had signs 
only in lower limbs. This indicates the presence of subclinical neuropathy in 
asymptomatic sites. 
9. Analysis of signs: Sensory signs: Sensory signs seen in our study were diminished 
vibration, touch, pain and temperature in that order. Mostly signs were present below 
ankle, and in some patients below knee. Only in few patients, especially in CIDP group 
signs were present in hand.  In 17 patients all modalities like vibration, touch, pain and 
temperature were lost in lower limbs. In 8 patients, only vibration impairment was seen 
(Ref.Table.2.17). In 3 patients, sensory signs were present in hands, mainly vibration 
impairment. 
Motor signs: Predominant motor sign was abnormal ankle jerk, which was diminished in 
6 patients and absent in 11 patients. In some patients (4 patients), diminished knee jerk 
was noted. Weakness in ankle dorsiflexion and plantar flexion was seen in 2 patients, 
weakness in extension of great toe seen in 4 patients and in some (7 patients), toe-grip 
was weak (Ref table 2.18) and in 3 patients, wasting in foot intrinsic muscles was seen. In 
upper limbs, signs were not seen except in 2 CIDP patients, who showed both sensory 
and motor findings. Like wise CIDP patients had both proximal and distal weakness in 
lower limbs. Both sensory and motor signs present in our study are similar to what 
described in literature [66]. 
10. Electrophysiological study:  
Nerve conduction study was done only in 30 (50%) patients as many patients 
refused for nerve conduction study. Only those patients, who were having symptoms of 
peripheral neuropathy, were willing to undergo electrophysiological study.  
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Among 60 patients, 23 patients (38.3%) had both symptoms and signs of 
peripheral neuropathy and 2 patients, even though did not have symptoms, showed signs 
of peripheral neuropathy on clinical examination nerve conduction study confirmed this.  
Among those patients who neither had symptoms nor signs of peripheral 
neuropathy, 5 patients were studied after counseling them and 1 of these 5 patients (20%) 
showed electrophysiological evidence of peripheral neuropathy. This indicates subclinical 
neuropathy may be present in 20% of HIV infected patients. However this is a group of 
small number and it has to be evaluated with large number of patients.   
In those patients who were having symptoms of peripheral neuropathy (23/26), all 
had clinical and Electrophysiological evidence of Peripheral Neuropathy (p-value: 
0.0001) (sensitivity 88.5%). And 2 patients who didn’t have symptoms, but showed signs 
on examination. And all 25 patients with signs of peripheral neuropathy were having 
electrophysiological evidence of peripheral neuropathy. So detailed history and 
neurological examination is necessary in all HIV infected patients.  
Nerve conduction study was done totally in 30 patients. Among them, 
electrophysiological evidence of peripheral neuropathy was seen in 26 patients. 
Predominant pattern seen was mixed neuropathy (both axonal and demyelination), which 
was seen in 18 patients.  (Ref table 2.19) But in literature predominant pattern seen is 
Axonal [53, 67]. Among the 5 patients with CIDP, 1 patient had features of both axonal 
and demyelination pattern and others showed predominant demyelination pattern. 3 
patients showed only axonal pattern. Both motor and sensory neuropathy was seen in 24 
patients and only sensory neuropathy was seen in 2 patients.  
In 13 patients, electrophysiological evidence of peripheral neuropathy was seen in 
both upper limbs & lower limbs. In remaining 13 patients, only in lower limbs peripheral 
neuropathy features were present. But clinically many (20/23) had symptoms only in 
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lower limbs. (Ref table 2.20) It shows subclinical peripheral neuropathy may be present 
in upper limbs. In patients with distal symmetric polyneuropathy, electrophysiological 
evidence was predominantly seen in lower limbs (13 patients) and in remaining 7 patients 
was seen both in upper limbs and lower limbs. 
Comparing our study with other Indian study: 
NO FACTOR 
JYOTI GARG 
ET AL [53] 
OUR STUDY 
1. Total no. of patients 39 60 
2. 
Peripheral Neuropathy present 
in 
20 26 
3. 
Mean duration of 
HAART(months) 
24 19 
4. CD4   < 200 17 9 
 > 200 3 17 
5. Symptoms seen in 20 (100%) 23 (88%) 
6. Signs seen in 20 (100%) 25 (96%) 
7. 
Electrophysiological evidence 
of Peripheral Neuropathy seen 
4/20 26/26 
8. 
Pattern of Peripheral 
Neuropathy 
Distal symmetric  
polyneuropathy. 
Axonal pattern 
Commonly distal symmetric  
polyneuropathy, 
others:CIDP,MM.  Mixed 
pattern (both axonal and 
demyelinating) 
9. No. of patients on HAART 17/20 26/26 
10. 
Correlation between duration 
of HAART and peripheral 
neuropathy 
No significant 
relation 
less number of peripheral 
neuropathy patients seen in 
longer duration of HAART 
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Comparing our study with other international studies: 
NO. FACTOR 
BRAZIL STUDY 
[52] 
NEUROPHYSIO
LOGIC CLINIC 
DEC.1987 [51] 
OUR STUDY 
1. Total no. of patients 49 41 60 
2. M : F 32 : 17 - 33 : 27 
3. Mean age 36.8 - 35.6 
4. Age range (years) 21-53 - 21-54 
5. Peripheral Neuropathy seen in 34 (69.4%) 36 (88%) 26 (43.3%) 
6. 
Both symptoms and signs 
seen in 
12/34 - 23/26 
7. Only signs seen in 22/34 - 2/26 
8. 
Subclinical (no symptoms, no 
signs) Peripheral Neuropathy 
2 17 1/26 
9. Neurotoxic drug intake 32 (94.1%) - 18 (69.2%) 
10. 
Electrophysiological study 
done in 
39 - 30 
11. 
Peripheral Neuropathy seen in 
(among those underwent 
Electrophysiology) 
13/39 - 26/30 
12. Common type seen 
Distal Symmetric  
Polyneuropathy 
(8/13) 
Distal Symmetric  
Polyneuropathy 
Distal Symmetric  
Polyneuropathy 
(20/26) 
 
Some observations of our study go along with other studies. [55, 56]  For example 
the common type distal symmetric polyneuropathy seen in other studies [51,52,53] is also 
the common type in our study. Prevalence seen in our study is similar with other studies 
[69,70]. Unlike other studies [53], in our study, those having symptoms and signs were 
having electrophysiological evidence of peripheral neuropathy. In our study, male sex, 
advanced stage of disease and increasing age are associated with more risk of developing 
peripheral neuropathy (Ref. Table 2.22).  Also those on HAART of longer duration are 
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less affected with peripheral neuropathy. But these observations are not statistically 
significant. Only the positive symptom by history and increasing age are significantly 
associated with the occurrence of peripheral neuropathy. Like other studies [69] CD4 
count doesn’t correlate with prevalence of peripheral neuropathy. 
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Summary 
 
1. Prevalence of peripheral neuropathy in HIV infected patients in our study is 26/60 
(43.3%).  
2. In our study, peripheral neuropathy is seen more in patients with advanced clinical 
stage and increasing age. There is no increase in prevalence of peripheral 
neuropathy in patients with less CD4 count. But these observations, except the age 
of the patients, are not statistically significant.  
3. Peripheral neuropathy less commonly seen in patients on HAART of longer 
duration. As duration of HAART increases, peripheral neuropathy is seen more in 
stavudine users, suggesting drug toxicity is the cause for peripheral neuropathy 
rather than HIV-related. But this needs to be confirmed with neuropathological 
studies. 
4. Distal symmetrical polyneuropathy is the common type (20/26). Common 
pathological pattern of neuropathy is mixed (both axonal and demyelination) 
neuropathy (18/26). 
5. All patients who had symptoms of peripheral neuropathy had electrophysiological 
evidence of peripheral neuropathy. Likewise all patients with signs of peripheral 
neuropathy had electrophysiological evidence of peripheral neuropathy. Hence 
detailed history and clinical examination for symptoms and signs of peripheral 
neuropathy is essential in all HIV infected patients as it can pick up more number 
of patients with peripheral neuropathy earlier and so they can be treated earlier. 
 
6. Among the 5 patients (who didn’t have either symptoms or sings of peripheral 
neuropathy) who underwent nerve conduction study, 1 had electrophysiological 
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evidence of peripheral neuropathy. So subclinical peripheral neuropathy present in 
20% (1/5) of patients. But this needs to be evaluated with large number of 
patients. 
7. Numbness and tingling were the common and burning pain and pins and needles 
sensations were the less common symptoms seen in our patients. Diminished or 
absent ankle jerks, impaired vibration, touch, pain and temperature were the 
common signs. 
8. Symptoms and signs were more common in lower limbs than in upper limbs. 
 
 
 
 
 
 
 
 
Yes/No Duration 
Sugar 
[R] 
(mg%)
Urea (mg%) Creati.(mg%)
Hb 
(gm%) 
TC 
(C/cum
m)
PS-
megalob
last
AT 
Diag. Recent 
1 Perumal 30/M 45/07 ZLN 2Y III Nil Nil N - Nil 74 18 0.9 14 6000 Nil 172 402 ND Not Sugg. of PN. 
2 Murugan 39/M 387/07 
ZLE 
ZLN 1Y3M III Nil Nil Y 3M Y 79 17 1.0 11.7 7100 Nil 75 328 D DSP 
3 Periyathai 32/F 348/07 
SLN 
ZLN 2Y I Nil Nil N - Nil 63 18 1.0 12.6 4100 Nil 169 414 ND Not Sugg. of PN. 
4 Mariappan 39/M 147/09 
On 
ATT 5M III Nil ATT Y 3M Y 109 29 1.2 12.7 4300 Nil 70 35 D DSP 
5 Kathirvel 40/M 35/09 
ZLE 
ZLN 3M III Nil Nil Y 6M Y 88 19 1.5 11.4 5400 Nil 117 950 D CIDP
6 Anthoniyammal 40/F 382/07 SLN  1Y3M IV Nil Nil N - Nil 68 17 0.9 12.1 6000 Nil 547 1039 ND Not Sugg. of PN. 
7 Paul Durai 33/M 82/06 
SLE 
ZLN 3Y IV Nil Nil N - Nil 74 19 1.0 13.1 5600 Nil 15 672 ND Not Sugg. of PN. 
8 Jaganathan 41/M 103/09 
SLE 
ATT 5M IV Nil ATT Y 3M Y 93 14 1.0 11.3 4500 Nil 56 315 D DSP 
9 Kannu Pandiyan 39/M 9-Apr
SLN 
SLE 4Y III Nil ATT 6M Y 1Y Y 84 19 1.2 8 4400 Nil 371 97 D CIDP
10 Selvaraj 38/M 57/09 SLN 4M III Nil Nil N - Nil 66 16 1.0 10.8 8000 Nil 56 66 ND Not Sugg. of PN. 
Regi
men Duration 
Stage at 
Diagnos
is 
S.   
No. Pt's Name
Age (Y) 
/ S 
ART 
Centre 
No 
Dissertation on Peripheral Neuropathy in HIV Infected Patients 
Master Chart  (1)
Inference 
past H/O 
any 
illness
Any 
other 
drug 
intake
Signs 
of PN NCS
Symptoms of 
PN Investigations - Blood CD4 Count/μl
11 Jesudoss 36/M 280/06 
ZLE 
ZLN 2Y  9 M III Nil Nil N - Nil 78 33 0.9 14 3000 Nil 56 228 ND Not Sugg. of PN. 
12 Shanmugathai 23/F 203/08 SLN 1Y I Nil Nil N - Y 68 19 0.8 11.3 6000 Nil 286 722 D DSP 
13 Arumugam 38/M 95/08 SLN 1 Y 4 M III Nil Nil N - Nil 93 27 0.8 14 6500 Nil 150 160 ND Not Sugg. of PN. 
14 Murugan 30/M 381/07 
ZLE 
ZLN 1 Y  10 M I Nil Nil Y 4M Y 65 21 1 12.6 8600 Nil 834 259 D DSP 
15 Seetha 33/F 213/08 ZLN 1Y 4 M IV Nil Nil N - Nil 106 42 0.8 10.6 7200 Nil NA 280 ND Not Sugg. of PN. 
16 Chandra 40/F 156/09 ZLN 2M I Nil Nil N - Nil 103 24 0.9 12.1 6500 Nil NA 328 ND Not Sugg. of PN. 
17 Arumugam 40/M 251/09 ZLN 1M I Nil Nil Y 6M Y 63 23 0.9 13 11000 Nil 322 156 D DSP 
18 Rathnaselvam 36/F 252/08 
SLN 
ZLN 1Y III Nil Nil Y 1Y Y 62 16 1.1 11.2 8000 Nil 37 263 D DSP 
19 Thangaraj 32/M 178/08 
SLE 
ZLN 1Y 2M III Nil Nil N - Nil 91 24 1.2 10 4300 Ni 116 192 ND Not Sugg. of PN. 
20 Palavesam Balan 37/M 60/06 
SLE 
ZLN 3Y6M IV Nil Nil Y 3M Y 66 14 1.1 15 7000 Nil 76 948 D DSP 
21 Saravana Kumar 41/M 235/08 SLN 1Y III Nil Nil N - Nil 60 20 1.4 10 5000 Ni 34 218 ND Not Sugg. of PN. 
22 Balakrishnan 34/M 413/07 
ZLE 
ZLN 1 Y 10 M III Nil Nil N - Nil 114 16.0 1.2 14.7 6800 Ni 432 253 ND Not Sugg. of PN. 
23 Pitchammal 23/F 137/07 SLN 2Y 5M I Nil Nil N - Nil 74 22 1.4 10.7 7600 Nil 58 637 ND Not Sugg. of PN. 
24 Mallika 30/F 23/07 
SLE 
ZLN 2Y  6 M III Nil Nil N - Nil 96 30 1.1 11.8 6800 Nil 169 636 ND Not Sugg. of PN. 
25 Jayakodi 42/M 172/09 
ZLE 
ATT 3M III Nil ATT Y 2M Y 78 27 0.8 14.5 4400 Nil NA 242 D
Distal sensory 
poly neuropathy 
26 Mariyammal 42/F 154/06 ZLN 3M 6 M III Nil Nil N - Nil 63 16 0.6 8.4 4000 Nil 190 348 ND Not Sugg. of PN. 
27 Jecintha 33/F 14/07 ZLN 2Y 6 M I Nil Nil N - Nil 70 30 1.0 12 6500 Nil 339 411 D Not Sugg. of PN. 
28 Kandaraj 37/M 237/07 ZLN 2Y III Nil Nil N - Nil 80 40 1.6 13 8200 Nil 120 362 ND Not Sugg. of PN. 
29 Sumathy 24/F 744/06
SLN 
ZLN 3Y 6 M I Nil Nil N - Nil 69 19 0.9 12.5 8100 Nil 573 925 ND Not Sugg. of PN. 
30 Shanmugathai 46/F 334/08 
SLE 
SLN 10M III Nil Nil N - Nil 83 27 0.9 15.9 7000 Nil NA 395 ND Not Sugg. of PN. 
31 Shanmugaraj 30/M 197/07 
SLE 
ZLN 2Y III Nil Nil Y 6M Y 93 28 0.9 13 9000 Nil 46 512 D DSP 
32 Eswaran 36/M 97/09 ZLN 6M III Nil Nil Y 6M Y 68 16 0.9 11.5 4700 Nil 442 232 D DSP
33 Paul Pandi 41/M 279/06 
SLN 
ZLN 3 Y III Nil Nil N - Nil 71 23 0.8 14 7000 Nil 187 639 ND Not Sugg. of PN. 
34 Mariappan 36/M 240/08 ZLN 1Y III Nil Nil N - Nil 106 24 1.0 13.5 6200 Nil 95 142 ND Not Sugg. of PN. 
35 Prema 28/F 331/08
SLE 
SLN 9M IV Nil Nil Y 1Y Y 96 36 0.9 11.8 6300 Nil - 206 D DSP 
36 Esakki 45/M 350/08 
SLE 
SLN 10M III Nil Nil N - Nil 67 33 1.3 13 8100 Nil 39 200 ND Not Sugg. of PN. 
37 Indira 34/F 191/08 ZLE 1Y 3M III Nil Nil N - Nil 99 17 1.0 12.1 7400 Nil 397 471 ND Not Sugg. of PN. 
38 Samudrapandi 38/M 1423/06 
ZLE 
ZLN 2Y 6M III Nil Nil N - Nil 88 38 1.1 14.2 7600 Nil - 697 D
Distal sensory 
poly neuropathy 
39 Balasaraswathi 28/F 163/08 
SLN 
ZLN 1Y 3M I Nil Nil N - Nil 73 20 1.0 13.6 9500 Nil 360 654 D Not Sugg. of PN. 
40 Arumugam 28/M 440/07 ZLN 1Y 10M III Nil Nil N - Nil 65 18 0.8 12.8 5000 Nil 481 261 ND Not Sugg. of PN. 
41 Valarmathi 36/F 234/07 SLN 2Y 4M III Nil Nil Y 6M Y 81 26 1.0 12.5 7800 Nil 310 628 D DSP
42 Santhanamari 23/F 314/08 
SLE 
ZLN 1Y I Nil ATT N - Nil 60 21 0.7 11.6 7500 Nil 94 420 ND Not Sugg. of PN. 
43 Thangaselvi 31/F 82/09 SLN 8M III Nil Nil Y 1Y Y 78 34 1.0 11.2 4800 Nil NA 576 D CIDP
44 Radha 39/F 698/06 
ZLN  
SLN 1Y 6M I Nil Nil Y 6M Y 89 37 1.1 11.6 6200 Nil NA 214 D DSP
45 Ramakrishnan 54/M 389/07 
SLN 
ZLN 2Y III Nil Nil Y 2M Y 64 34 1.3 11.7 7400 Nil 49 145 D MM
46 Uikattan 51/M 161/07
SLE 
SLN 2Y 4M III Nil Nil Y 6M Y 109 15 0.9 11.2 6500 Nil 139 195 D CIDP
47 Chellappa 32/M 63/06 ZLN 3Y 8 M I Nil Nil N - Nil 63 19 0.8 10 7100 Nil 161 282 ND Not Sugg. of PN. 
48 Indira 43/F 341/07 SLN 2Y 2 M I Nil Nil N - Nil 106 16 0.9 12.6 6200 Nil NA 563 D Not Sugg. of PN. 
49 Petchiyammal 38/F 425/07
ZLE 
ZLN 2Y I Nil Nil N - Nil 65 38 0.9 11.7 6900 Nil 248 705 ND Not Sugg. of PN 
50 Rathinamathy 33./F 007/08 SLN 1Y 9M I Nil Nil N - Nil 76 20 0.9 9.8 6600 Nil 260 734 ND Not sugg. of PN 
51 Pitchammal 21/F 137/07 SLN 2Y 6M I Nil Nil Y 1Y Y 74 22 1.1 10.7 7600 Nil 58 402 D DSP
52 Selvin 35/M 337/06 
SLN 
ZLN 4Y III Nil Nil N - Nil 83 36 1.1 12.1 6000 Nil 14 830 ND Not sugg. of PN 
53
Umaya 
Velayutham 41/M 138/08 SLN 1Y 6M III Nil Nil Y 2M Y 101 20 1.3 14 7200 Nil NA 268 D DSP
54 Kalaiselvi 31/F 35/08 ZLN 1Y II Nil Nil Y 3M Y 95 32 0.9 11.6 7600 Nil NA 219 D DSP
55 Mariappan 37/M 263/06 
ZLE 
ZLN 3Y 3M II Nil Nil N - Nil 84 24 0.8 14 7400 Nil 168 700 ND Not sugg. of PN 
56 Shenbagam 52/F 249/09 ZLN 3M I NIl Nil N - Y 98 40 1.3 10.8 6300 Nil - 339 D DSP
57 Manoharan 41/M 94/06 
ZLE 
SLN 3Y 9 M III Nil Nil Y 6M Y 93 37 1.1 13.6 7000 Nil NA 424 D CIDP
58 Parameshwari 25/F 21/07 ZLN 2Y 11M I Nil Nil N - Nil 87 34 1.1 13.5 7400 Nil 663 791 ND Not sugg. of PN 
59 Krishnammal 33/F 003/09 ZLN 9M I Nil Nil N - Nil 93 38 1.0 11.6 5800 Nil NA 415 D Not sugg. of PN 
60 Therirajan 43/M 49/06
SLN 
ZLN 3Y 11M IV Nil Nil Y 6M Y 86 42 1 11.9 6200 Nil NA 256 D DSP
DSP - Distal Symmetric Polyneuropathy,     CIDP  - Chronic  Inflammatory Demyelinating Polyradiculoneuropathy,     MM - Mononeuritis Multiplex,   PN  - Peripheral Neuropathy, Y-years, M-months, D-done, ND-not done, NA- n
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1 387/07 Murugan Right 3.9 2.4 21.0 47.9 Not Right 2.5 15.0 4.6 47.2
Median 9.4 1.9 19.9 formed Median 
Left 3.2 6.5 15.3 50.1 Not Left 2.3 13.8 3.2 47.2
Median 8.3 6.2 16.5 formed Median 
Right 3.0 6.7 8.5 33.0 Not Both surals Not  recordable 
Tibial 12.7 6.4 8.3 formed 
Left 4.5 1.7 10.2 26.8 Not 
Tibial 17.1 0.4 7.3 formed 
2 147/09 Mariappan Right 3.0 4.4 14.1 54.6 Not Right 2.3 15.2 3.2 57.8
Median 7.6 5.1 14.5 formed Median 
Left 3.7 5.7 4.9 57.2 Not Left 2.0 12.9 2.9 61.2
Ulnar 8.0 4.9 5.0 formed Median 
Right 4.5 14.0 9.0 40.3 Not Both surals  not recordable 
Tibial 12.9 17.7 9.1 formed 
Left 4.8 4.2 9.0 46.1 Not 
Peroneal 12.6 3.3 10.7 formed 
3 35/09 Kathirvel Right 3.0 5.7 11.4 57.1 Not Right 2.4 7.5 2.3 50.4
Median 7.4 4.8 10.7 formed Median 
Left 2.5 6.9 13.9 51.0 Not Left 1.9 8.6 2.9 56.1
Ulnar 7.4 6.9 13.4 formed Ulnar 
Right 3.3 6.0 9.7 46.1 Not Right 5.9 0.9 1.0 25.3
Peroneal 11.4 7.0 11.8 formed Sural 
Left 2.8 10.9 7.5 42.5 Not Left 5.8 31.0 3.1 18.7
Tibial 11.9 9.0 7.7 formed Sup.Peroneal 
4 103/09 Jega - Right 4.0 7.8 14.4 56.4 32.1 Right 2.4 22.0 3.2 52.9
Nathan Ulnar 8.8 7.4 18.2 Median 
Left 3.5 7.8 15.8 57.6 Not Left 2.0 7.5 3.7 53.9
Median 7.7 7.2 17.1 formed Ulnar 
Right 4.5 8.5 8.9 28.0 62.0 Right sural and Left Superficial Peroneal not recordable 
Tibial 16.3 6.9 10.5
Left 3.9 3.0 16.2 33.0 39.0
Peroneal 13.5 2.5 18.0
SNC
Dissertation on Peripheral Neuropathy in HIV Infected Patients 
Master Chart  (2)
No
ART 
Centre 
No
Patient's 
Name
MNC 
5 4/09. Kannu - Right 2.9 13.8 17.3 52.4 Not Right 3.0 13.5 2.8 37.2
Pandiyan Median 7.5 13.4 17.7 formed Median 
Left 2.8 17.5 13.4 53.6 Not Left 2.6 16.6 2.8 42.0
Median 7.3 16.5 13.8 formed Median 
Right 4.1 2.0 8.0 24.6 Not left 6.2 5.9 0.3 24.3
Peroneal 17.1 1.0 4.8 formed Sural 
Left 4.3 8.7 8.9 34.6 Not Right NR 
Tibial 14.7 6.5 9.9 formed Sural 
6 203/08. Shanmuga - Right 2.5 11.1 13.1 55.6 24.5 Right 2.4 18.6 3.8 45.5
Thai Median 6.5 10.8 13.5 Median 
Left 1.7 10.0 12.9 56.7 26.3 Left 1.6 5.4 2.1 63.3
Ulnar 5.3 9.9 12.2 Ulnar 
Right 1.9 5.8 7.2 46.6 Not Right NR 
Peroneal 8.9 3.7 6.2 formed Sural 
Right 3.1 14.2 6.8 49.2 Not Left NR 
Tibial 11.3 11.6 7.7 formed Sural 
Left 2.0 2.1 8.2 48.7 Not 
Peroneal 8.8 1.6 9.0 formed 
Left 3.1 15.3 8.9 43.5 Not 
Tibial 10.9 11.7 9.8 formed 
7 381/07 Murugan Right 2.4 6.2 13.9 50.1 29.9 Right 2.2 27.7 2.6 50.7
Ulnar 7.2 5.0 14.5 Median 
Left 3.0 10.0 14.7 59.1 Not Right 1.9 14.5 2.4 48.4
Median 7.1 10.2 13.3 formed Ulnar 
Left 4.3 11.2 7.0 55.8 30.7 Left 2.0 15.2 2.3 56.1
Ulnar 8.8 8.0 9.6 Median 
Right 2.7 1.7 14.1 46.1 Not Left 2.0 5.4 3.8 49.0
Peroneal 10.5 1.3 16.8 formed Ulnar 
Right 3.8 22.9 8.1 42.3 47.9 Right 3.2 4.0 2.0 44.2
Tibial 12.5 18.4 9.4 Sural 
Left 2.9 6.0 13.1 42.7 Not Left 2.8 4.2 2.0 53.8
Peroneal 10.4 5.6 14.6 formed Sural 
8 251/09 Arumugam Right 2.5 11.6 11.3 58.1 26.2 Right 2.2 11.6 3.0 50.6
Median 5.9 11.3 10.9 Median 
Left 2.4 8.2 12.3 68.7 29.8 Left 2.0 8.2 4.1 49.5
Ulnar 6.0 12.2 12.9 Ulnar 
Right 2.5 6.3 11.7 40.2 Not Left 6.3 4.7 1.5 23.7
Peroneal 11.5 5.2 12.8 formed Sural 
Right 3.3 9.3 11.8 37.0 56.8 Right NR 
Tibial 13.3 11.1 11.8 Sural 
Left 4.4 2.2 15.9 40.8 Not 
Peroneal 12.7 1.7 15.3 formed 
Left 4.5 9.2 8.8 36.4 58.1
Tibial 15.2 10.6 9.4
9 252/08 Rathina - Right 3.3 12.0 9.2 53.9 28.9 Right 2.5 10.0 2.5 43.3
Selvam Ulnar 7.6 11.0 9.1 Median 
Left 2.6 16.6 9.5 51.2 27.1 Left 2.8 32.4 3.3 35.8
Median 7.3 13.9 10.4 Ulnar 
Right 3.2 5.2 9.7 45.7 Not Right 3.9 1.3 0.3 38.3
Peroneal 12.0 4.5 10.3 formed Sural 
Left 3.1 17.5 8.3 39.0 Not Left NR 
Tibial 12.6 14.4 8.0 formed Sural 
10 60/06 Palavesam Right 2.2 10.2 16.2 55.6 29.2 Right 2.1 22.7 3.8 52.3
Balan Median 6.2 10.2 16.4 Median 
Left 2.4 8.6 14.3 63.2 27.8 Left 1.5 10.7 3.1 66.7
Ulnar 6.0 8.6 16.6 Ulnar 
Right 4.1 3.0 10.4 37.4 Not Left 4.1 1.8 2.0 36.4
Tibial 14.5 7.9 10.8 formed Sural 
Left Not Stimulatable Right NR 
Peroneal Sural 
Right Not Stimulatable
Peroneal 
Left 4.3 12.5 9.3 37.2 Not 
Tibial 15.3 12.3 9.2 formed 
11 172/09 Jayakodi Right 3.7 12.3 16.4 51.5 29.6 Right 2.6 4.6 2.5 42.0
Median 8.1 11.9 18.1 Median 
Left 2.7 8.8 12.9 56.8 30.6 Left 2.0 10.5 3.4 51.0
Ulnar 7.3 8.0 13.9 Ulnar 
Right 4.2 4.0 9.2 43.8 52.0 Right NR 
Tibial 12.6 4.2 12.3 Sural 
Left 3.4 12.6 9.8 42.3 51.6 Left NR 
Tibial 11.2 11.2 10.2 Sural 
12 14/07 Jecintha Right 2.4 18.2 11.2 57.7 24.8 Right 1.9 10.3 2.7 57.3
Median 6.0 17.4 11.5 Median 
Left 3.3 6.6 10.6 62.0 24.8 Left 1.4 3.1 2.6 70.4
Ulnar 6.9 6.3 11.1 Ulnar 
Right 2.5 8.1 9.2 52.8 Not Right 4.3 7.8 3.9 39.2
Peroneal 8.8 7.9 10.4 formed Sural 
Left 2.5 2.5 8.5 44.8 53.4 Left 4.0 8.2 3.8 40.4
Tibial 10.3 4.3 8.1 Sural 
13 197/07 Shanmuga- Right 3.7 6.5 14.9 52.0 Not Right 2.5 13.2 3.5 48.0
Raj Median 8.7 6.2 16.2 formed Median 
Left 3.3 9.3 11.9 49.9 30.7 Left 1.9 12.9 2.9 53.2
Ulnar 8.5 7.8 10.8 Ulnar 
Right Not Elicitable Right NR 
Peroneal Sural 
Left Not Elicitable Left NR 
Tibial Sural 
14 97/09 Eswaran Right 3.3 7.4 12.7 50.2 27.8 Right 2.6 9.1 4.9 42.6
Median 7.7 6.4 13.3 Median 
Left 3.0 6.7 14.0 57.6 28.3 Right 2.0 11.3 3.4 49.0
Ulnar 7.2 7.4 14.3 Ulnar 
Right 6.6 1.3 17.7 35.4 Not Left 2.0 29.3 2.9 55.0
Peroneal 15.3 0.8 13.4 formed Median 
Left 5.6 8.8 10.7 40.1 50.8 Left 4.9 1.2 1.4 30.2
Tibial 13.8 8.0 10.7 Sural 
Right 3.8 27.3 2.9 39.6
Sural 
15 331/08 Prema Right 2.7 14.4 19.8 50.2 30.8 Right 2.3 15.0 2.8 47.2
Median 7.3 13.6 19.0 Median 
Left 2.6 7.1 9.6 46.1 31.2 Left 2.0 7.4 3.8 53.9
Ulnar 8.0 7.1 8.1 Ulnar 
Right 3.1 2.5 10.9 35.8 Not Right NR 
Peroneal 11.8 2.0 10.0 formed Sural 
Left 3.3 14.4 10.4 36.6 Not Left NR 
Tibial 12.1 11.4 10.6 formed Sural 
16 1423/06 Samudra Right 2.2 12.9 13.4 55.6 25.2 Right 2.2 14.4 2.5 49.8
Pandi Median 6.2 12.6 13.9 Median 
Left 4.3 8.2 11.6 60.0 30.9 Left 2.0 8.8 4.0 50.0
Ulnar 8.4 12.1 10.5 Ulnar 
Left 3.7 15.7 8.0 45.9 45.4 Right NR 
Tibial 10.8 13.0 9.2 Sural 
Left NR 
Sural 
17 163/08 Bala  Right 2.1 9.9 12.1 76.2 25.4 Left 2.5 19.9 3.9 43.3
Saraswathy Ulnar 5.1 9.4 12.2 Median 
Left 2.4 12.3 11.4 58.3 23.3 Right 1.5 6.7 2.2 66.7
Median 5.8 11.9 11.0 Ulnar 
Right 2.3 3.6 7.7 51.2 Not Left 3.1 6.5 1.7 48.1
Peroneal 8.5 5.2 9.0 formed Sural 
Left 3.7 21.0 8.9 43.3 50.5 Right 3.8 6.3 1.9 46.3
Tibial 11.0 22.2 8.9 Sural 
18 234/07 Valar- Right 3.7 11.6 12.6 65.0 27.5 Right 2.9 7.4 0.8 38.2
mathy Median 7.2 10.4 13.7 Median 
Left 1.9 4.5 10.6 52.6 26.7 Left 1.7 6.3 3.3 59.9
Ulnar 6.3 3.0 10.5 Ulnar 
Right 2.9 4.2 10.4 42.0 48.1 Right NR 
Peroneal 11.3 4.3 12.7 Sural 
Left 3.2 6.7 8.3 35.3 52.6 Left NR 
Tibial 12.3 6.4 8.8 Sural 
19 82/09 Thanga- Right 2.5 13.6 12.3 52.5 29.5 Right 2.4 8.7 3.7 45.5
selvi Median 6.9 13.4 12.5 Median 
Left 2.1 8.5 11.3 54.5 Not Left 2.0 9.3 2.0 51.0
Ulnar 6.7 8.7 10.5 formed Ulnar 
Right 2.0 6.6 10.2 38.6 Not Right NR 
Peroneal 11.0 5.3 10.6 formed Sural 
Left 3.7 12.8 7.1 34.9 Not Left NR 
Tibial 13.1 10.5 7.9 formed Sural 
20 698/06 Radha Right 3.1 10.2 15.8 52.5 25.6 Right 2.4 22.6 3.5 45.5
Median 7.5 9.5 16.5 Median 
Left 2.3 11.2 14.4 53.9 27.7 Left 2.0 7.2 2.4 51.0
Ulnar 6.6 11.1 13.5 Ulnar 
Right 2.4 4.3 14.5 40.5 Not Right 3.4 3.8 3.5 44.4
Peroneal 10.3 3.2 13.7 formed Sural 
Left 4.6 13.4 9.4 35.4 53.3 Left NR 
Tibial 13.3 12.3 11.3 Sural 
21 389/07 Rama- Right 3.3 10.7 11.4 46.9 29.8 Right 2.5 9.6 3.5 48.9
Krishnan Median 8.0 10.1 11.5 Median 
Left 4.4 4.3 10.0 51.1 30.0 Left 3.0 7.6 2.0 33.8
Ulnar 9.3 4.4 9.6 Ulnar 
Right 2.6 3.4 9.7 40.2 53 Left 3.8 0.7 0.8 40.0
Peroneal 11.6 2.8 9.4 Sural 
Left 3.0 7.0 6.8 37.3 Not Right 3.2 6.1 2.8 47.3
Tibial 11.9 7.4 8.2 formed Sural 
22 161/07 Uikattan Right 4.5 8.6 8.7 54.2 29.7 Right 1.8 12.2 3.0 54.6
Ulnar 8.5 7.5 10.2 Ulnar 
Left 2.9 9.5 10.6 43.7 Not Left 2.3 16.9 2.6 48.9
Median 7.5 9.0 12.4 formed Median 
Right 2.4 2.2 5.7 38.0 Not Left 3.8 5.2 2.7 39.6
Peroneal 11.4 1.9 6.6 formed Sural 
Left 2.9 7.9 9.2 37.1 58.8 Right NR 
Tibial 12.1 6.3 8.8 Sural 
23 341/07 Indira Right 2.7 11.3 14.4 50.4 29.4 Right 2.4 24.4 2.8 45.5
Median 6.9 10.4 15.8 Median 
Left 3.7 8.2 10.6 50.3 27.3 Left 1.8 25.4 2.1 57.1
Median 8.0 6.6 9.6 Ulnar 
Right 3.1 6.2 11.4 43.2 47.9 Right 4.0 8.0 4.0 37.5
Peroneal 10.5 6.1 13.2 Sural 
Left 5.6 5.7 7.1 50.6 49.1 Left 5.4 3.7 2.8 37.1
Tibial 11.4 2.3 10.0 Sural 
24 137/07 Pitchammal Right 3.4 14.3 13.9 50.5 27.3 Right 2.8 9.3 2.9 40.0
Median 7.6 14.1 14.3 Median 
Left 4.8 5.0 4.8 52.8 26.7 Left 1.7 14.9 2.5 58.5
Ulnar 9.0 5.1 4.9 Ulnar 
Right 2.8 6.3 12.1 40.1 Not Right NR 
Peroneal 11.0 6.7 12.1 formed Sural 
Left 4.1 15.0 11.0 40.5 44.5 Left NR 
Tibial 11.5 18.2 12.7 Sural 
25 138/08 Umaya- Right 3.0 12.8 11.6 48.0 29.8 Right 2.3 6.9 2.6 48.0
velayudham Median 7.6 13.3 11.6 Median 
Left 4.3 4.1 5.6 48.0 27.6 Left 2.1 11.1 2.5 47.2
Ulnar 8.9 3.8 5.4 Ulnar 
Right 2.1 5.2 9.9 38.4 Not Left 5.7 13.8 1.9 26.5
Peroneal 9.9 4.2 11.2 formed Sural 
Left 3.4 15.5 9.1 38.4 49.8 Right NR 
Tibial 11.8 13.0 10.0 Sural 
26 35/08 Kalai- Right 2.5 11.4 14.4 54.6 Not Right 2.2 6.1 2.3 50.7
selvi Median 6.4 10.2 13.9 formed Median 
Left 5.2 13.6 10.0 56.0 27.4 Left 1.7 4.5 3.7 59.9
Ulnar 9.0 13.0 10.0 Ulnar 
Right 2.2 7.2 10.7 41.1 Not Right NR 
Peroneal 9.5 5.5 10.4 formed Sural 
Left 3.4 8.2 11.5 37.2 Not Left NR 
Tibial 10.4 7.9 12.1 formed Sural 
27 249/09 Shenbagam Right 2.7 13.2 12.3 51.7 31.2 Right 2.2 16.4 3.6 50.1
Median 6.8 12.8 12.8 Median 
Left 2.7 3.3 10.4 50.4 29.8 Left 2.1 7.5 2.5 48.1
Ulnar 6.9 3.2 9.9 Ulnar 
Right 2.8 7.4 10.0 40.7 52.5 Right NR 
Peroneal 10.4 7.8 9.7 Sural 
Left 3.9 10.4 8.9 32.8 54.5 Left NR 
Tibial 12.4 9.5 9.8 Sural 
28 94/06 Manoharan Right 2.7 15.6 19.8 50.2 30.6 Right 2.3 8.1 3.5 48.0
Median 7.3 14.5 19.0 Median 
Left 3.1 7.8 12.2 51.2 32.1 Left 2.8 7.3 4.3 35.8
Ulnar 7.8 8.0 12.4 Ulnar 
Right 2.0 5.6 14.4 36.0 Not Right NR 
Peroneal 11.2 4.3 12.3 formed Sural 
Left 6.4 6.8 6.6 34.9 Not Left NR 
Tibial 15.5 4.9 7.6 formed Sural 
29 003/09 Krish - Right 2.4 13.7 13.7 54.2 24.3 Right 1.9 28.8 3.1 58.5
nammal Median 6.5 13.5 10.8 Median 
Left 2.1 10.0 14.6 63.0 26.4 Left 1.5 14.0 2.6 66.7
Ulnar 5.7 10.4 16.9 Ulnar 
Right 3.8 18.6 8.5 42.5 47.8 Right 3.8 8.0 4.1 38.7
Tibial 11.0 15.7 9.7 Sural 
Left 5.3 2.5 8.2 49.4 47.8 Left 2.8 3.6 2.1 53.8
Peroneal 12.4 1.8 9.9 Sural 
30 49/06 Therirajan Right 2.8 11.9 13.7 53.6 Not Right 2.1 16.7 2.6 51.9
Median 7.3 11.5 13.8 formed Median 
Left 2.6 2.7 10.6 56.1 Not Left 1.9 12.5 2.6 52.1
Ulnar 6.9 1.8 11.5 formed Ulnar 
Right 4.3 6.6 9.5 34.6 Not Right NR 
Tibial 14.7 5.0 10.6 formed Sural 
Left 4.1 3.9 11.0 48.0 Not Left NR 
Peroneal 10.5 2.1 13.1 formed Sural 
NR -  Not Recordable 
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